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1. INTRODUCTION 
Improving drug absorption is one of the main goals of pharmaceutical research. The 
pharmacokinetics and barrier penetration of a large number of active molecules are not 
satisfactory. To increase drug bioavailability pharmaceutical excipients, like absorption 
enhancers are often used. They improve drug solubility and absorption, protect active 
ingredients and delay drug release. In addition excipients can reduce the amounts of applied 
active agents, and by lowering inter-individual variability in systemic exposure increase the 
prediction of pharmacological effects. There is a need for new, innovative absorption 
enhancers with more favorable properties and better pharmaceutical profile. Our research 
and my Ph.D. thesis focus on investigation and comparison of clinically applied and novel 
pharmaceutical excipients using in vitro culture models of the intestinal and vascular 
barriers. 
1.1. Factors influencing drug bioavailability 
Several factors influence the bioavailability of drugs, such as physicochemical 
properties, mainly the low solubility and high molecular size, poor permeability through 
biological barriers, the application sites, binding to plasma proteins, degradation by 
enzymes, or the excretion by renal or other organ activity (Fig. 1) (Aungst, 2012).  
 
 
Figure 1. Determining factors of drug bioavailability. 
Generally, large molecules, like peptides and protein drugs, have low bioavailability 
because biological barriers hinder their penetration. The oral absorption of peptides is low, 
only 1.6 % of insulin (Mw: 5808 Da) and 1.4 % of calcitonin (Mw: 3400 Da) become 
available systemically (Sarmento et al., 2007; Buclin et al., 2002). Not only molecular size, 
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but solubility properties also strongly influence the absorption of drugs. Due to insufficient 
lipophilicity the partition into biological membranes of very hydrophilic, low-molecular 
weight agents is low resulting in unsatisfied permeability. However, the cellular uptake of 
highly lipophilic compounds is also hindered because they cannot dissolve in aqueous fluids 
in the body. For the optimum absorption, pharmaceuticals need both sufficient hydrophilicity 
to dissolve in aqueous fluids and adequate lipid solubility to facilitate their partitioning into 
the plasma membranes of cells. Molecular charge or hydrogen bonding groups also influence 
the permeability of drugs (Deák et al., 2006). 
Biological barriers like the skin, the intestinal, blood-fetal or blood-brain barriers 
separate the organism from the external environment and the body compartments from each 
other. They control the transport of molecules, especially nutrients, and protect the organism 
from microbes and xenobiotics. Different barriers have different properties regarding to drug 
penetration therefore the bioavailability of pharmacons also depends on the site and mode of 
application. High drug utilization can be reached by injection into the blood or other local 
sites, but patient acceptance is low. Alternative non-invasive administration routes can be 
also effective, drug delivery through the nasal pathway can result in high and quick serum 
drug concentration elevation, similarly to intravenous injection (Kürti et al., 2013). 
Since only the absorbed unbound drugs execute their effect on the body, drug 
interaction with plasma proteins (e.g. human serum albumin, globulin, glycoproteins) reduce 
the free drug concentration in blood, therefore the pharmacological availability (Oravcová et 
al., 1996). Finally, cellular, renal and hepatic metabolism and excretion to urine, feces, and 
bile decrease the drug content in the blood and eliminate it from the organs. Increasing the 
residence time by delayed release or lowering the metabolism by inhibiting enzyme activity 
can enhance the pharmacological utilization of drugs (Renukuntla et al., 2013). 
Understanding the factors contributing to the absorption and effectiveness of drugs (Fig. 1) 
helps to select pharmaco-technological approaches to improve bioavailability.  
Transport pathways across biological barriers 
Penetration of drugs across epithelial or endothelial barriers is mediated by several 
pathways, like passive diffusion, carrier or receptor mediated transport, and active efflux 
(Fig. 2). Passive penetration involves the diffusion of drugs in the direction of a 
concentration gradient, while carrier and receptor mediated transports move agents against 
concentration gradients (Sugano et al. 2010). The passive diffusion of pharmaceuticals 
through barriers can occur by combination of two pathways, the transcellular, across the 
cells, and paracellular routes, across the junctions between adjacent cells (Fig. 2). For 
lipophilic drugs the transcellular pathway is the major route due to their high affinity for the 
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lipid bilayer of cell membrane. The transcellular penetration of hydrophilic molecules is 
blocked because they cannot interact with the lipid plasma membrane. At the paracellular 
pathway the permeability of drugs is modulated by tight junction (TJ) proteins which seal 
the gaps between cells. The transmembrane junctional proteins include the claudins, 
occludin, tricellulin, junctional adhesion molecules, and endothelial cell-selective adhesion 
molecule (Deli; 2009). They are anchored to the cytoplasmic filaments by scaffolding 
proteins like zonula occludens-1 or -2 (ZO-1; ZO-2) and dynamically modulated by several 
signaling pathways. The penetration of low molecular weight hydrophilic molecules at the 
paracellular route depends on the tightness of the intercellular junctions determined by the 
expression profile of junctional proteins and the lipid composition of the barrier (Deli, 2009). 
 
 
Figure 2. Transport pathways through the intestinal barrier. Red, SLC transporter; green, efflux transporter; 
purple: receptor 
Membrane proteins greatly contribute to the transcellular permeation of drugs. There 
are more than 400 transporter proteins belonging to two major superfamilies of membrane 
transporters: the solute carrier (SLC) and ATP-binding cassette (ABC) transporter 
families. SLC uptake transporters are mainly co-transporters and many are driven by ion 
gradient. ABC transporters require ATP binding and hydrolysis for their function. 
Facilitated transport is driven by substrate gradient and involves a transporter protein, such 
as glucose or hexose transporter GLUT1. The carrier mediated transport is more selective 
for molecules, it is stereo and enantiospecific, in contrast to passive diffusion, where the 
physicochemical parameters are the main determinants rather than the conformation of 
molecules. Among SLC transporters about two dozen are related to drug disposition 
(Sugano et al., 2010). SLC influx transporters like OATP-A, PEPT1 or LAT1 can enhance 
the uptake of active molecules (Giacomini et al., 2010). LAT1 amino acid transporter 
delivers L-DOPA a neurotransmitter prodrug (Peura et al., 2013), and the antibiotic 
ampicillin is a substrate of PEPT1 peptide transporter (Lafforgue et al., 2008). ABC efflux 
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transporters such as P-glycoprotein (Pgp), breast cancer resistance protein (BCRP), or 
multidrug resistance-associated protein-1, -2, -3 (MRP1-3) transporters are important 
members of the defense system against xenobiotics providing chemical immunity for the 
body (Schinkel et al., 2003). They also recognize and eliminate a wide range of different 
drugs, especially at the level of the blood-brain and intestinal barriers, the kidney and the 
liver (Giacomini et al., 2010). Receptors are also suitable to deliver large molecules, 
including recombinant proteins and peptides through barriers via receptor mediated 
transport (Pardridge, 2012). It is worth noting that the passive and carrier mediated drug 
transports coexist and that the passive permeation is a significant factor in the absorption 
of drug-like molecules (Sugano et al., 2010).  
1.2. Drug transport across the intestinal barrier 
The different biological properties of epithelial and endothelial barriers determine drug 
permeability which can differ greatly (Ward et al., 2000). Transepithelial resistance (TEER) 
reflects the paracellular ion flux through barriers and indicates their tightness. The strongest 
barriers in the body are formed by brain capillaries and skin epithelial cells (Deli, 2009). The 
mucous layer of the gastrointestinal (GI) tract represents an intermediate tightness with 
highly variable barrier properties in individual anatomical parts. Small intestine, where the 
majority of nutrient uptake occurs, possesses the lowest resistance values reflecting leaky 
barrier, while colon have intermediate tightness. Because the main focus of this work is 
improving drug delivery across the intestinal barrier, only this biological barrier is discussed 
in detail. 
Oral drug delivery is the most popular mode for treating diseases. It is safe, efficient, 
and patient compliance is good. However, drug absorption is restricted by TJs connecting 
intestinal epithelial cells. Cell membrane permeability is a major determinant of drug 
penetration (Aungst, 2012; Sugano et al., 2010), but paracellular transport also has a big 
impact on drug penetration (Deli, 2009). The extent of drug absorption greatly differs 
between regions of the GI tract due to dissimilar anatomical structures, distinct lipid 
composition of cellular membranes, and different expression pattern of TJ proteins (Chiba et 
al., 2008) and uptake and efflux transporters (Renukuntla et al., 2013; Deli, 2009). The 
jejunum and ileum shows the highest drug absorption rate because of more permeable TJs 
compared with other parts of the GI tract (Ward et al., 2000). Furthermore, microvilli in the 
apical part of epithelial cells multiply the absorptive surface area of small intestine two to 
four-folds compared to colon (Masaoka et al., 2006). The major limitations of the per os 
administration route include the acidic environment and enzymes in the stomach, which 
degrade sensitive molecules, especially peptide or protein based drugs (Renukuntla et al., 
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2013). Drugs absorbed from the small and large intestines enter into the portal vein and 
reach the liver where the active agents can be metabolized by the hepatobiliary system 
further lowering drug bioavailability. 
1.3. Models for the prediction of intestinal drug absorption 
It is crucial to assess the permeability properties of new active agents or drug 
candidates in the early phase of drug development (Vastag et al., 2009). There are several 
models for the prediction of intestinal drug absorption (Fig. 3). In silico screening is a rapid, 
cheap and high throughput method, but at present it cannot give accurate predictions for 
transporters (Vastag et al., 2009; Deli, 2011). In vitro methods, like the octanol-water 
partitioning or the parallel artificial membrane penetration assay (PAMPA) are also suitable 
for screening permeability based on the physicochemical properties of drugs. 
 
 
Figure 3. Models for the prediction of intestinal drug absorption 
In vitro cell culture assays are screening systems with higher complexity. Epithelial 
cell lines, such as the human Caco-2 model are better alternatives for predicting intestinal 
drug absorption and are routinely used in drug development (Artursson et al., 1997). They 
express many SLC and ABC transporters therefore they are suitable to test carrier mediated 
and active efflux transport as well. The Caco-2 cell line (Fig. 4) is a well characterized 
model of the epithelium of small intestine (Hubatsch et al., 2007). Cells are polarized, grow 
in monolayer, possess microvilli, make tight connections with adjacent cells and express 
many nutrient and efflux transporters such as P-gp (Artursson et al., 2001; Englund et al., 
2006). Caco-2 cells are widely used to measure drug penetration and data correlate well with 
in vivo drug absorption, mostly in case of passive transcellular pathway (Artursson et al., 
2001; Hellinger et al., 2010). Furthermore, the Caco-2 model is approved by the Food and 
Drug Administration for the identification of P-gp substrates (FDA Guidance for Industry, 
Drug Interaction Studies, 2012). Caco-2 cells selected by vinblastine show more uniform 
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cell morphology, express higher level of P-gp than native Caco-2 cells, and are excellent for 
screening efflux pump ligands (Hellinger et al., 2010). 
 
 
Figure 4. Images of vinblastine selected Caco-2 cells (Hellinger et al., 2012): (a) Electronmicrograph of Caco-2 
cells showing a tight junction (arrow); (b) immunostaining for β-catenin adherens junction protein (red); (c) 
immunostaining for P-glycoprotein efflux pump (green) and ZO-1 tight junction linker protein (red). β-CAT, β-
catenin; D, desmosome; P-GP, P-glycoprotein; TJ, tight junction; V, villus ;ZO1, Zonula occludens protein-1. 
Ex vivo or in situ models, such as everted sac, Ussing chamber and intestinal perfusion 
methods use intact tissue from laboratory animals and are also applied for drug investigation. 
These more complex intestinal models can better predict drug absorption than in vitro 
PAMPA or cell culture techniques, but they are more complicated and expensive. In vivo 
animal studies are also widely used, mainly in the last stage of drug development. 
1.4. Absorption enhancers 
Agents with low permeability may need assistance for their penetration through 
barriers. Absorption enhancers are compounds that improve the absorption of drugs and 
enhance their bioavailability. An optimal enhancer should possess the following 
characteristics: safe and non-toxic, chemically and pharmacologically inert, non-irritant, 
non-allergenic, outstanding and reversible permeation enhancement (Renukuntla et al., 
2013). These essential factors determining the success of permeation enhancers are in the 
focus of in-depth investigations for the pharmaceutically used and novel absorption 
enhancers. 
Methods to increase intestinal drug delivery 
Intestinal absorption enhancers can improve the pharmacological utilization of drugs 
by several mechanisms: (i) increasing drug solubility; (ii) opening the tight junctions; (iii) 
temporarily disturbing the lipid bilayer packing or fluidizing membranes; (iv) complexation 
or ion pairing; (v) preventing degradation/metabolism (Fig. 5; Renukuntla et al., 2013; 
Aungst, 2012).  
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Figure 5. Effects of absorption enhancers 
Solubilization of drugs increases the dissolved molecules and the distributions of drugs 
in the liquids. Molecular form of active agents cross barriers or penetrate cells better. There 
are many well characterized and effective excipients in pharmaceutical technology for 
solubilizing lipophilic pharmacons, like surfactants, fatty acids or cyclodextrines (Strickley, 
2004). They enhance the dissolution of drugs, like the immunosuppressant cyclosporin A, 
antineoplastic paclitaxel or etoposide, and antiviral lopinavir or ritonavir, resulting in higher 
bioavailability. 
A wide variety of compounds show TJ modulator properties, such as surfactants, 
chelators, cationic polymers, nitric oxide donors, bacterial toxins, or peptides (Deli, 2009). 
They reversibly open intracellular junctions and increase the paracellular flux of molecules. 
Modulators can directly act on TJ proteins and open the intercellular cleft, like the non-toxic 
peptide fragments of Clostridium perfringens enterotoxin (Sonoda et al., 1999). 
Cyclodextrines (Kiss et al., 2007) or cationic chitosans (Smith et al., 2005) indirectly 
modulate TJs. Anionic-, ionic-, non-ionic surfactants or bile salts were extensively studied to 
enhance transepithelial permeability, but their effects on TJs were less characterized. 
Transcellular permeation enhancement requires the modification of plasma membranes. 
Surfactants acting as absorption enhancers partition into epithelial cell membranes and 
change the packing of lipids (Swenson and Curatolo, 1992). Bile salts, like sodium cholate 
or taurocholate increase transcellular permability by changing the lipid composition of 
membranes. Complex formation or ion pairing also enhance the cellular permeability of 
drugs; lipophilic cyclodextrins such as the methylated derivatives (Loftsson et al., 2007), or 
counter-ion and drug pairs like 1-hydroxy-2-naphtoic acid and guanidino oseltamivir (Miller 
et al., 2010) help the encapsulated or linked drugs to cross the plasma membrane of cells. 
Degradation or metabolism of pharmacons might be prevented by encapsulation to 
protect against intestinal enzymes or by the pH-dependent controlled release of drugs. 
Surfactants are suitable to encapsulate and protect pharmacons, because above critical 
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micellarization concentration (CMC) they self-aggregate in defined orientation and form 
micelles (Narang et al., 2007). 
1.4. Non-ionic surfactants as drug absorption enhancers 
Surface active agents, or surfactants, are amphiphilic molecules possessing both 
lipophilic and hydrophilic residues. They are grouped by their physicochemical properties as 
anionic, cationic, non-ionic and zwitterionic surfactants. Anionic and non-ionic surfactants 
are the most applied excipients in the pharmaceutical industry and they are widely used as 
solubilizing agents in oral, injectable and nasal formulations (Table 1; Strickley, 2004; 
Dredán et al., 1998; Fedina et al., 1998). Many studies reviewed their absorption enhancer 
properties (Ganem-Quintanar et al., 1997; Aungst, 2012); they mostly increase the 
permeability through transcellular routes (Aungst, 2012), but there are data on their effect on 
TJs (Deli, 2009).  
 
Non-ionic surfactant Drug Trade name Classification 
Cremophor RH Cyclosporine A Neoral Immunosuppressant 
Cremophor EL 
Paclitaxel 
Ritonavir 
Taxol 
Norvir 
Antineoplastic 
Antiviral (HIV) 
Tween 80 
Cyclosporine A 
Sirolimus 
Etoposide 
Genraf 
Rapamune 
VePesid 
Immunosuppressant 
Immunosuppressant 
Antineoplastic 
TPGS Amprenavir Agenerase Antiviral (HIV) 
Solutol HS-15 
Diclofenac 
Propanidid 
- 
Panitol 
NSAID 
General anestethic 
Table 1. Examples for non-ionic surfactants in commercially available oral or injectable formulations (Strickley, 
2004). Abbrevation: HIV, human immunodeficiency virus; NSAID, non-steroidal anti-inflammatory drug 
Chemically non-ionic surfactants include derivatives of ethylene oxide or propylene 
oxide with alcohols, alkyl phenols, sucrose esters, and fatty acids. These surfactants, widely 
studied in pharmaceutical research, possess advantageous properties and many of them are 
used in commercially available drug formulation for decades (Table 1). Non-ionic 
surfactants are generally recognized as safe (Williams and Barry, 2004). This goup of 
excipients are good solubilizers of drugs (Strickley, 2004), have absorption enhancer 
properties (Aungst, 2000), and some of them were described as efflux pump inhibitor 
(Cornaire et al., 2004; Nerurkar et al., 1997).  
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Cremophors  
Chremophor, or as recently renamed Kolliphor, is a family of ionic and non-ionic 
emulsifiers and a registered trademark of BASF SE (Ludwigshafen, Germany). In 
pharmaceutical research and industry Cremophor EL, RH40 and RH60, ethoxylated 
derivatives of castor oil, are the most often used excipients (Fig. 5).  
 
 
Figure 5. Chemical structure of Chremophor RH40 and EL 
Cremophor RH40 (Table 1 and 2) is used in oral formulations, such as in Neoral 
(Novartis, East Hanover, NJ), in microemulsions (Cao et al., 2011), in self-emulsifying drug 
delivery systems (Gursoy and Benita, 2004), and in buccoadhesive tablets (Sakeer et al., 
2010). Cremophor RH40 in transdermal systems enhances the absorption of ketoprofen (Rhee 
et al., 2001) and theophylline (Zhao et al., 2006). It was also used as an absorption enhancer in 
nasal formulations in our previous research (Horvát et al., 2009). Cremophor EL (Fig. 5; 
Table 1 and 2) is used in infusions (Taxol), oral capsules (Gengraf), as well as in solutions. It 
is a well known solubilizer and penetration enhancer (Flaten et al., 2008), moreover inhibition 
of efflux pumps by Cremophor EL was also described (Nerurkar et al., 1997). 
Table 2. Properties of Tween 80 and Cremophor RH40 and Cremophor EL. Abbreviation: CMC, critical 
micellarization concentration; HLB, hydrophilic-lipophilic balance; Ph.Eur., European Pharmacopoeia. 
1
, 
Nerurkar et al., 1997; 
2
, Christiansen et al., 2010; 
3
,Christiansen et al., 2011 
 
Polysorbate 80 
(Ph.Eur.) 
Macrogol-
glycerolhydroxystearate 
40 (Ph.Eur.) 
Macrogolglycerol 
Ricinoleate (Ph.Eur.) 
Trade name Tween 80 Cremophor RH40 Cremophor EL 
Chemical 
name 
polyethoxylatedsorbitan 
and oleic acid 
polyethoxylated 40 
hydrogenated castor oil 
polyoxyl 35 castor oil 
R- carbon 
chain lenght 
18 18 18 
HLB 15 15 12-14 
CMC 50-63µg/ml
1,2
 390 µg/ml
3
 100 µg/ml
3
 
Solubility water soluble water soluble water soluble 
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During the clinical application of Cremophor EL containing infusions side effects were 
observed and there are efforts to find solubilizers and absorption enhancers with better 
profile (Gelderblom et al., 2001). 
Tweens 
Tweens, also known as polysorbates, are hydrophilic emulsifying agents and used by 
food, cosmetic and pharmaceutical industry. It is a group of ethoxylated sorbitan fatty acids. 
Tween 80 (Fig. 6 and Table 2) is commonly used as wetting, solubilizing and emulsifying 
agent in immediate-release solid and liquid dosage forms (Dredan et al., 1998). It can also 
act as an absorption enhancer. The permeability of cimetidine, furosemide, ranitidine 
hydrochloride, hydrochlorothiazide, and a model peptide was significantly increased by 
Tween 80 through Caco-2 cells (Rege et al., 2001, Nerurkar et al., 1997). Digoxin uptake 
was enhanced by Tween 80 in an ex vivo model (Cornaire et al., 2004). Tween 80 inhibits P-
gp efflux transporter (Nerurkar et al., 1997). 
 
 
Figure 6. Chemical structure of Tween 80 
Sucrose fatty acid esters 
Sucrose esters, composed of sucrose and fatty acids, are natural molecules produced by 
plants and microorganisms (Table 3; Daudé et al., 2012). Their potential application for drug 
delivery as solubilizers and stabilizer or absorption enhancers is widely researched. Sucrose 
esters were successfully tested in many different formulations like in suspensions (Yokoi et 
al., 2005), microemulsions (Thevenin et al., 1996), elastic vesicles (Honeywell-Nguyen et 
al., 2003), nanoemulsions (Klang et al., 2011). Due to their excellent solubilizing properties 
they increase the dissolution of a wide variety of drugs resulting higher bioavailability (Szűts 
et al., 2012). 
As absorption enhancers sucrose esters were mainly investigated for transdermal delivery 
(Csóka et al., 2007), but there are studies for oral, nasal and ocular applications as reviewed by 
Szűts and Szabó-Révész (2012). Investigating their permeability enhancer properties for 
intestinal drug delivery, sucrose fatty acid esters significantly increased the absorption of 
daunomycin, calcitonine, lidocain hydrochloride, cyclosporine A, and dextran in cell cultures or 
animal studies (Takaishi et al., 2006; Nakada et al., 1988; Ganem-Quintanar et al., 1998; Lerk et 
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al., 1993; Onishi et al., 2012). Sucrose esters were also described as efflux pump inhibitors but 
results are contradictory. Their effects on P-glycoprotein were tested in epithelial cells and in 
animal experiments (Cornaire et al, 2010; Hanke et al., 2004), but Takaishi et al. (2006) 
suggested that they do not inhibit efflux pumps. 
 
 P-1695 M-1695 D-1216 
Chemical 
structure 
 
Trade name Ryoto sugar ester P-1695 Ryoto sugar ester M-1695 
Surfhope SE Pharma D-
1216 (US DMF) 
Chemical 
name 
palmitate sucrose ester myristate sucrose ester laurate sucrose ester 
R- carbon 
chain lenght 
16 14 12 
HLB 16 16 16 
CMC 28-250 µM 
1
 28-250 µM 
1
 500 µg/ml 
2
 
Solubility water soluble water soluble water soluble 
Table 3. Properties of sucrose fatty acid esters. Abbreviation: CMC, critical micellarization concentration; HLB, 
hydrophilic-lipophilic balance; Ph.Eur., European Pharmacopoeia. 
1
, Molinier et al., 2005; 
2
, Christiansen et al., 
2010; 
3
,Christiansen et al., 2011 
1.4. Aims 
The main aim of the work was to reveal the complex mechanisms of the effect of non-
ionic surface active agents, especially water soluble sucrose esters on drug penetration across 
the intestinal barrier using culture models. Three selected sucrose esters, potential novel 
pharmaceutical excipients, were compared to Tween 80, Cremophor RH40 and 
Cremophor EL, reference surfactants, used in various medicinal products. The major aims of 
the experimental study were the following: 
(I) investigation and comparison of the effects of surfactants on intestinal 
epithelial and vascular endothelial cell viability 
(II) measurement of the effects of surfactants on drug permeability  
(III) identification of the pathways for the drug penetration enhancement on 
intestinal barrier model 
(IV) detailed analysis of intercellular tight junction morphology and membrane fluidity 
(V) determination of the effects of surfactants on efflux pump activity 
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2. MATERIALS AND METHODS 
2.1. Materials 
All reagents were purchased from Sigma-Aldrich Ltd. (Budapest, Hungary), unless 
otherwise indicated. Laurate sucrose ester (D-1216) was of pharmaceutical grade, palmitate (P-
1695) and myristate (M-1695) sucrose esters were of analytical grade (Mitsubishi Kagaku Foods 
Co., Tokyo Japan). Tween 80, Cremophor RH40 and Cremophor EL (BASF, Ludwigshafen am 
Rhein, Germany) were of pharmaceutical grade and used as reference surfactants. Buffers used 
in the experiments were: phosphate buffer saline (PBS) (136 mM NaCl, 6.5 mM Na2HPO4, 
2.7 mM KCl, 1.5 mM KH2PO4); Ringer-Hepes buffer (150 mM NaCl, 6 mM NaHCO3, 5.2 mM 
KCl, 2.2 mM CaCl2, 0.2 mM MgCl2, 2.8 mM D-glucose, 5 mM Hepes, pH 7.4). 
2.2. Cell culture 
Caco-2 Human intestinal epithelial cell line (ATCC cat.no. HTB-37, USA), human 
hCMEC/D3 brain endothelial cell line (Weksler et al. 2013), human uterine sarcoma lines 
MES-SA and its doxorubicin-selected derivative MES-SA/Dx5, and primary rat brain 
endothelial cells were used in the experiments. Caco-2 cells were grown in Eagle’s minimal 
essential medium (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 10 % 
fetal bovine serum (Lonza, Basel, Switzerland), 1% sodium-pyruvate (Gibco, Life 
Technologies, Carlsbad, CA, USA) and 50 μg/ml gentamicin in a humidified 37°C incubator 
with 5 % CO2. To obtain a more uniform morphology and higher efflux pump expression 
cells were treated with vinblastine (10 nM) for at least 6 passages as described by Hellinger 
et al. (2010 and 2012). D3 cells were grown in Endothelial Basal Medium-2 containing 
Endothelial Growth Medium-2 BulletKit (Lonza, Basel, Switzerland) supplemented with 
2.5 % fetal bovine serum in a humidified 37°C incubator with 5 % CO2. Primary cultures of 
brain endothelial cells were isolated from 3-weeks-old rats described by Veszelka et al. 
(2007). Cells were seeded in culture dishes at a density of 5 × 10
4
 cells/cm
2
 and the medium 
was changed every 2 days. When cells reached approximately 80-90 % confluence in the 
dish they were subcultured with 0.05 % trypsin-EDTA solution. For electric resistance 
measurements, permeability studies and electron microscopy Caco-2 cells were cultured on 
Transwell inserts (polycarbonate membrane, 0.4 µm pore size, 1.12 cm
2
 surface area, 
Corning Life Sciences, Tewksbury, MA, USA). For staining of nuclei, junctions and F-actin 
cells were grown on glass coverslips (Menzel-Gläser, Braunschweig, Germany). Surfaces 
were coated with 0.05 % rat tail collagen before cell seeding, unless otherwise indicated. 
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Human uterine sarcoma lines MES-SA, and its doxorubicin-selected derivative expressing 
high levels of P-gp (MES-SA/Dx5) were used for testing P-gp functionality (Chen et al., 1994). 
Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Life Technologies, 
Carlsbad, CA, USA) supplemented with 10 % fetal bovine serum, 5 mM L-glutamine and 50 
u/ml penicillin/streptomycin. To maintain homogenous P-gp expression, MES-SA/Dx5 cells 
were treated with 500 nM doxorubicin for at least 2 passages before the experiments. 
2.3. In vitro viability studies 
Different methods were applied to determine the effects of non-ionic surfactants on 
cell viability: MTT dye conversion, lactate dehydrogenase release (LDH) measurement, 
double fluorescent staining of cell nuclei. Real-time cell impedance measurement also 
provided information on cell viability. 
2.3.1. Treatment concentrations and intervals 
The treatment concentrations of sucrose esters P-1695, M-1695 and D-1216 varied 
between 3-3,000 µg/ml. Tween 80, Cremophor RH40 and Cremophor EL were used in 1-
100,000 µg/ml concentrations. All treatment solutions were prepared or diluted in DMEM 
without phenol red. Untreated cells (control group) received only culture medium. Triton X-
100 (10 mg/ml) was used as a toxicity control. The cells were treated for 1 and 24 hours. 
2.3.2. MTT dye conversion  
The yellow 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye is 
taken up by cells and converted by mitochondrial and cytoplasmic enzymes into blue 
formazan crystals (Fig. 7, Liu et al. 1997). The dye conversion rate determines cell metabolic 
activity and viability. Caco-2 epithelial and hCMEC/D3 endothelial cells were cultured in 
96-well plates (Orange Scientific, Braine-l’Alleud, Belgium) for 3 days. Confluent cultures 
were treated and incubated with surfactants for 1 and 24 hours. Then cells were washed with 
PBS and incubated with 0.5 mg/ml MTT solution in phenol red free DMEM for 3 hours in a 
CO2 incubator. The amount of formazan converted by cells was dissolved in dimethyl-
sulfoxide (DMSO) and determined by measuring absorbance at 595 nm wavelength with a 
microplate reader (Fluostar Optima, BMG Labtechnologies, Ortenberg, Germany). Cell 
viability was calculated as percentage of dye conversion by non-treated cells. 
 
14 
 
Figure 7. Cell viability assays: MTT dye conversion, LDH release measurement, and double fluorescent cell 
nuclei staining. Abbreviations: LDH, lactate dehydrogenase; H33342, Bis-Benzimide; EthD-1, ethidium 
homodimer-1; yellow star: membrane damage 
2.3.3. LDH release measurement 
The release of LDH enzyme, the indicator of cell membrane damage (Fig. 7), was 
determined from culture supernants by Cytotoxicity Detection Kit/LDH (Roche, Basel, 
Switzerland). Caco-2 or hCMEC/D3 cells were cultured in 96-well plates for 3 days then 
treated for 1 or 24 hours with surfactants. After treatments 50 μl samples from culture 
supernatants were incubated with equal amounts of reaction mixture for 15 minutes. The 
enzyme reaction was stopped by 0.1 M HCl. Absorbance was measured at a wavelength of 
492 nm with a microplate reader (Fluostar Optima, BMG Labtechnologies, Ortenberg, 
Germany). Cell death was calculated as percentage of the total LDH release from cells 
treated by Triton X-100. The non-toxic concentrations (TC0), 50 % toxic concentrations 
(TC50) and concentrations causing death in all cell (TC100) were calculated from fitted 
curves (GraphPad Prism 5.0, GraphPad Software Inc., San Diego, CA, USA). The detailed 
description of calculation is shown in Appendix (Pub. III, Supporting Information Eq. 1-2). 
2.3.4. Double fluorescent staining of cell nuclei 
Cell viability was also determined by a morphological test: bis-benzimide (Hoechst 
33342) labels all cell nuclei blue, ethidium-homodimer-1 (Molecular Probes, USA) stains 
only dead cells red (Fig. 7). Caco-2 and primary rat brain endothelial cells grown on glass 
coverslips were treated with Cremophor RH40 and EL for 1 and 24 hours. Thirty minutes 
before the end of treatments 10 µM bis-benzimide and ethidium-homodimer-1 were added to 
the cells. Cells were fixed in 4 % paraformaldehyde in PBS, and processed for TJ 
immunostaining. At the end of immunostaining coverslips were mounted by Fluoromount. 
The fluorescent stainings of epithelial cells were detected by Leica SP5 confocal microscope 
(Leica Microsystems CMS GmbH, Germany). Stainings of primary brain endothelial cells 
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were examined by a NikonEclipse TE2000 fluorescent microscope (Nikon, Japan) and 
photographed by a Spot RT digital camera (Diagnostic Instruments, USA). 
2.4. Fluorescent actin-labeling and immunostainings for junctional proteins 
Treatments induced changes in morphology and cell-cell connections of Caco-2 cells 
were confirmed by immunostaining for tight junction proteins claudin-1 and -4, cytoplasmic 
linker protein ZO-1 and adherens junction protein β-catenin. Filamentous actin (F-actin) was 
stained in intestinal culture model by fluorescently labeled phalloidin and cell nuclei by bis-
benzimide dye. The morphology of TJ was also investigated in primary rat brain endothelial 
cells by immunostaining for claudin-5 protein. Cell layers were grown on glass coverslips 
and treated with absorption enhancers (P-1695 30 µg/ml, M-1695 60 µg/ml, D-1216 
100 µg/ml, Tween 80 1000 µg/ml, Cremophor RH40 1000 µg/ml or Cremophor EL 
1000 µg/ml) for 1 hour. Cytochalasin D, an inhibitor of actin polymerization was applied at 
2 µg/ml concentration. After treatments the cultures were washed twice in PBS and fixed 
with 4 % paraformaldehyde-PBS for 30 minutes. Cells were permeabilized with 0.2 % 
Triton X-100 and blocked with 3 % bovine serum albumin-PBS. Cells were washed three 
times with PBS between each step.  The fixed cells were incubated with primary antibodies 
anti-claudin-1, anti-claudin-4, anti-claudin-5, anti-ZO-1 or anti-β-catenin (Life 
Technologies, Carlsbad, CA, USA) overnight. Incubation with secondary antibody Cy3-
labeled anti-rabbit IgG, and Alexa Fluor 488 Phalloidin (Life Technologies, Carlsbad, CA, 
USA) and bis-benzimide lasted for 1 hour. Between and after incubations cells were washed 
three times with PBS. Coverslips were mounted by Fluoromount. Stainings for claudin-1, 
claudin-4, ZO-1and β-catenin were examined by a Leica SP5 confocal microscope, while 
claudin-5 stainings were detected by a NikonEclipse TE2000 fluorescent microscope and 
photographed by a Spot RT digital camera. 
2.5. Electron microscopy 
Cells grown on culture inserts were treated with absorption enhancers (P-1695 30 µg/ml, 
M-1695 60 µg/ml, D-1216 100 µg/ml, Tween 80 and Cremophor RH40 1000 µg/ml) for 1 hour. 
After treatments cells were washed by PBS and fixed with 3 % paraformaldehyde containing 
0.5 % glutaraldehyde in cacodylate buffer (pH 7.4) for 30 min at 4°C. After washing with the 
buffer several times, cells were postfixed in 1 % OsO4 for 30 min. Following a rinse with 
distilled water, the cells were dehydrated in graded ethanol, block-stained with 1 % uranyl 
acetate in 50 % ethanol for 1 h. After the last step of dehydration, inserts were placed in the 1:1 
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mixture of ethanol and Taab 812 (Taab; Aldermaston, Berks, UK) for 30 min at 30°C. Finally, 
the membranes of the culture inserts with the cells were removed from their support and 
embedded in Taab 812. Polymerization was performed overnight at 60°C. Ultrathin sections 
were cut perpendicularly for the membrane using a Leica UCT ultramicrotome (Leica 
Microsystems, Milton Keynes, UK) and examined using a Hitachi 7100 transmission electron 
microscope (Hitachi Ltd., Tokyo, Japan) 
2.6. Impedance measurement 
Measurement of the impedance dynamically monitors living cells. The RTCA SP 
instrument (ACEA Biosciences, San Diego, USA) measures impedance at 10 kHz, which  
derives from interaction between cells and electrodes of 96-well E-plates (ACEA 
Biosciences). This interaction correlates with cell proliferation, viability or with transcellular 
ion flux in real-time (Fig. 8; Atienza et al. 2006; Ózsvári et al., 2010; Benson et al., 2013). 
Background readings were performed before cell seeding, then cells were dispensed at the 
density of 1×10
4
 cells/well, and grown until confluency. Impedance was measured every 2 
minutes following treatments. For ion flux measurement the impedance at each time point 
was defined as Rn - Rb. For the toxicity measurement of Cremophors cell index at each time 
point was calculated from the following equation: (Rn - Rb)/15, where Rn is the cell-electrode 
impedance of the well when it contains cells and Rb is the background impedance of the well 
with culture medium alone. Cell indices (CI) were normalized to the latest time point before 
treatment of each groups (CIn / CIbefore treatment). 
 
 
Figure 8. Cellular pathways of ion currents in case of impedance and resistance. Thick arrows show the main 
route of the ions. Abbreviation: ECM, extracellular matrix; TJ, tight junction 
17 
2.7. Measurement of electrical resistance of cell layers 
Transepithelial electrical resistance (TEER), was measured by an EVOM resistance 
meter using STX-2 electrodes (World Precision Instruments Inc., Sarasota, FL, USA) and 
expressed relative to the surface area (Ω × cm2). TEER represents the paracellular 
permeability of cell layers for ions (Fig. 8). The TEER of Caco-2 monolayers was 800±138 
Ω × cm2 (mean±SD; n=158) after 3 weeks of culture. Resistance measurements were carried 
out before and after permeability studies to investigate the effect of surfactants on ion flux 
through cellular junctions. 
2.8. Permeability study 
The flux of the drugs caffeine, antipyrine, atenolol, vinblastine and fluorescent dyes 
fluorescein and rhodamine 123 across epithelial cell layers was determined in apical to basal 
(AB) direction (Fig. 9). The flux of vinblastine, fluorescein and rhodamine 123 was also 
measured in basal to apical (BA) direction (Fig. 9). Caco-2 cells were seeded onto Transwell 
filter inserts and the resistance of the cell layers was checked twice a week. After 21 days 
when the resistance was high and stable, the inserts were transferred to 12-well plates 
containing 1.5 ml Ringer–Hepes solution in the basolateral compartments. In apical 
chambers culture medium was replaced by 500 μl Ringer–Hepes containing drugs or marker 
molecules with or without absorption enhancers. Drugs and rhodamine 123 were used at the 
concentration of 10 µM, fluorescein was administered at 10 µg/ml concentration. Absorption 
enhancers were applied in the apical compartment in the following concentrations: Tween 80 
and Cremophor RH40 at 30, 60, 100, 1000 µg/ml, P-1695 and M-1695 at 30, 60 µg/ml, and 
D-1216 at 30, 60, 100 µg/ml. The plates were kept in a CO2 incubator on a rocking platform 
(100 rpm) for 1 hour in case of atenolol, caffeine, antipyrine and rhodamine 123. For 
vinblastine and fluorescein 2-hour permeability test was performed, and samples were taken 
from the acceptor phase at both 1 and 2 hour time points. After the incubation samples from 
the upper and lower compartments were collected and the concentrations of fluorescein and 
rhodamine 123 were determined by a fluorescent microplate reader (Fluostar Optima) while 
drug concentrations were measured by HPLC, as detailed below. The apparent permeability 
coefficients (Papp) in AB and BA directions, and the clearance of the molecules were 
calculated (Appendix, Pub. III, Supporting Information Eq. 3-7). 
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Figure 9. Schematic images about permeability study in both AB and BA directions. Abbreviation: AB, apical to 
basal direction; BA, basal to apical direction. 
2.9. HPLC analytical procedures 
Analytical measurements were performed on a Merck-Hitachi LaChrom HPLC system 
equipped with UV and fluorescence detector (Merck, Darmstadt, Germany). Antipyrine and 
vinblastine were determined by using Purospher C18e 125 mm x 3 mm (5 μm) column 
(Merck, Darmstadt, Germany) operated at 0.5 ml/min flow rate, maintained at 40 °C. Mobile 
phase for antipyrine consisted of 40 % methanol in 0.1 M ammonium acetate with isocratic 
elution. UV detection was at 250 nm wavelength. The calibration curve showed a good 
linearity within the examined concentration range of 0.1-10 μM (r2 = 0.999). For vinblastine, 
elution was applied to a mixture of 250 ml methanol, 200 ml 25 nM ammonium-acetate and 
3 ml 10 % trifluoroacetic acid. Vinblastine was quantified at 275/360 nm excitation/emission 
wavelengths. The calibration curve was linear with an r
2
 = 0.998 in the range of 0.01-1 μM. 
Samples with higher than 1 μM vinblastine concentration were 10x diluted in Ringer–Hepes 
solution. HPLC measurement of caffeine was performed using Purospher C18e 
125 mm x 4 mm (5 μm) column (Merck, Darmstadt, Germany) operated at 0.8 ml/min flow 
rate, maintained at 35°C. Mobile phase was 15 % methanol in 0.1 M ammonium acetate. UV 
detection was at 275 nm. The r
2
 of the calibration curve was 0.999 in the concentration range 
of 0.1-10 μM. Samples with atenolol were injected onto a Gemini C18e 150 mm x 3 mm (5 
μm) column (Phenomenex Inc., Aschaffenburg, Germany) operated at 35°C and at an eluent 
flow rate of 0.5 ml/min. Elution was applied to a mixture of 300 ml methanol, 400 ml 0.1 M 
ammoniumacetate, 20 ml 10 % ammonium hydroxide and 2 ml 0.1 M Na2EDTA. Atenolol 
was quantified at 230/300 nm excitation/emission wavelengths. The calibration curve was 
linear with an r
2
 = 0.999 in the range of 0.01-1 μM. Samples with higher than 1 μM atenolol 
concentration were diluted 10x in Ringer-Hepes solution. 
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2.10. Measurement of plasma membrane fluidity in Caco-2 cells 
Caco-2 cells were collected by trypsinization, washed twice and resuspended in PBS. 
The density of cells was set by absorbance measurement at 360 nm to OD360=0.1 (Hewlett 
Packard 8452A Diode Array Spectrophotometer). Cells were labeled with 0.2 µM TMA-
DPH (1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene; Molecular Probes, Life 
Technologies) for 5 minutes. Fluorescence anisotropy was measured on a T-format 
fluorescence spectrometer (Quanta Master QM-1, Photon Technology International, 
Princeton, NJ, USA) (Török et al., 1997; Balogh et al., 2011). Excitation and emission 
wavelengths were 360 and 430 nm, respectively (5-nm slits). Cells were kept at 37°C under 
stirring conditions. Anisotropy data were acquired in every second. After 5 minutes the 
lowest concentrations of treatment solutions were added rapidly to the cell suspension and 
every 3 minutes the treatment concentration was increased during anisotropy measurements. 
Control cells received only vehicle. A strong membrane fluidizer, benzyl alcohol (30 mM); 
(Merck, Darmstadt, Germany) was used as a positive control in the experiments. The 
following treatment concentrations were applied: 1, 10, 30, 60, 100 µg/ml for sucrose ester, 
and 1, 10, 100, 1000 µg/ml for Tween 80 and Cremophor RH40. The average of 50 
anisotropy measurements in the last 1 minute of each treatment concentration was calculated 
and compared to the anisotropy of the vehicle-treated cells at the same time point. 
2.11. Measurement of efflux pump activity 
The activity of efflux pumps was determined by cellular accumulation of 
rhodamine 123 and calcein AM (Life Technologies, Carlsbad, CA, USA) in Caco-2 
epithelial cells grown in 24-well plates for 2 days (seeding density: 10
5
 cells/well). Cells 
were pre-incubated with Ringer-Hepes buffer for 20 minutes. Treatments with surfactants, P-
1695 (30 µg/ml), M-1695 (60 µg/ml), D-1216 (100 µg/ml), Tween 80 (1000 µg/ml), 
Cremophor RH40 (1000 µg/ml) or efflux pump inhibitors, verapamil (100 µM) and 
cyclosporin A (10 µM) were performed in the presence of rhodamine 123 for 1 hour. 
Following incubations cells were washed three times with ice cold PBS and lysed with 
0.1 M NaOH. Rhodamine 123 concentration was determined by a fluorescent microplate 
reader (excitation wavelength: 485 nm, emission wavelength: 520 nm; Fluostar Optima).  
The calcein AM assay can be used for the measurement of the activity of efflux 
transporters P-gp, MRP-1 and MRP-2 (Juvale et al, 2012; Hanke et al, 2010). The cellular 
transport of the non-fluorescent calcein AM is inhibited by efflux transporters, therefore only 
limited amount gets into the cells where intracellular esterases convert the dye to a fluorescent 
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metabolite. For calcein AM assay Caco-2 cells were seeded on 96-well plate (cell density: 
7×10
4
 cells/well) and grew for 24 hours. Before experiments cells were pre-incubated with 
Ringer-Hepes for 20 minutes. Treatments with surfactants or efflux pump inhibitors were 
performed in the presence of 1.25 µM calcein AM. Fluorescence was immediately measured 
by a microplate reader at 5 minutes interval for 1 hour (excitation wavelength: 485 nm; 
emission wavelength: 520 nm). The fluorescence intensity was calculated as percentage of the 
control group. 
To estimate the effect of sucrose esters on P-glycoprotein functionality, calcein 
accumulation was measured in the presence of the test substrates in MES-SA and MES-
SA/Dx5 cells (Karászi et al., 2001; Türk et al., 2009). Cells (2 x 10
5 
cells/100µl) were 
preincubated with verapamil (100 µM), P-1695 (30 µg/ml), M-1695 (30 µg/ml), D-1216 
(100 µg/ml), Tween 80 (100 µg/ml), Cremophor RH40 (1000 µg/ml) or with solvent DMSO 
(less than 0.1%) for 5 min at 37°C. M-1695 and Tween 80 were applied in lower concentrations 
due to different sensitivity of sarcoma cells as compared to Caco-2 cells. Thereafter 0.25 µM 
calcein AM was added and the cells were incubated for 10 min at 37°C. Cells were gated based 
on TO-PRO3 positivity (Life Technologies, Carlsbad, CA, USA). Samples were measured by a 
FACSCalibur™ flow cytometer (BD Biosciences, San Jose, CA, USA). 
2.12. Statistical analysis 
All data presented are means ± SD. Values were compared using analysis of variance 
(ANOVA) followed by Dunnett’s test (GraphPad Prism 5.0, GraphPad Software Inc., San 
Diego, CA, USA). In case of fluorescein, vinblastine, and rhodamine 123 permeability and 
TMA-DPH anisotropy measurements two-way ANOVA followed by Bonferroni posttest was 
applied. Changes were considered statistically significant at P < 0.05. All experiments were 
repeated at least two times, the number of parallel samples varied between 4 and 12. 
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3. RESULTS 
3.1. Effects of non-ionic surfactants on viability of intestinal epithelial and vascular 
endothelial cells 
The toxic effects of Cremophor RH40 and EL were investigated and compared by 
different methods and in wide concentration range on Caco-2 and hCMEC/D3 cell lines and 
pimary rat brain endothelial cells. Colorimetric assays were carried out after treatments with 
Cremophors for 1 and 24 hours (Fig. 10). Epithelial cells remained viable and no membrane 
damage was observed after 1 hour treatment with surfactants (Fig. 10a). Cremophors at 10 and 
50 mg/ml concentrations elevated MTT dye conversion. After 24 hour treatment 
Cremophor RH40 at 50 mg/ml concentration reduced the viability of epithelial cells measured 
by MTT assay and Cremophor EL caused total cell death at the same concentration (Fig. 10b), 
indicating higher toxicity. The LDH enzyme leakage was increased after treatment by 
Cremophors (5-50 mg/ml) at 24-hour. 
 
 
Figure 10. Effects of Cremophor RH40 and EL (0.1-50 mg/ml) on human Caco-2 epithelial (a, b) and hCMEC/D3 
endothelial cells (s, d) measured by MTT dye conversion and LDH release methods. The MTT values were 
compared to non-treated group which was defined as 100 % viable. For LDH measurement the Triton-X 100 
treated group was considered as 100 % dead. Data are presented as mean ± S.D., n = 5; statistical analysis: 
ANOVA followed by Dunnett test; * P < 0.05, *** P < 0.001, all treatment groups were compared to control. 
CR, Cremophor RH40; CE, Cremophor EL. 
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Cremophor treatments for 1 hour did not decrease the viability of D3 endothelial cells 
measured by MTT and LDH assays (Fig. 10c-d). Surfactants (5-50 mg/ml, 1 hour) 
significantly increased MTT dye conversion of D3 endothelial cells similarly to Caco-2 cells 
(Fig. 10c). Both types of Cremophors (5-50 mg/ml) induced cellular damage in concentration 
dependent manner in endothelial cells after 24-hour treatments (Fig. 10d). MTT and LDH 
colorimetric assays confirmed on epithelial cells that Cremophor RH40 is less toxic than 
Cremophor EL. Vascular endothelial cells were more sensitive to treatments with surfactants 
than intestinal epithelial cells. Cremophors killed endothelial cells at 5 mg/ml and higher 
concentrations, while similar effect was observed at 50 mg/ml concentration in epithelial cells. 
 
 
Figure 11. Effects of Cremophor RH40 and EL (0.1-50 mg/ml) on human Caco-2 intestinal epithelial (a, b) and 
hCMEC/D3 endothelial (c, d) cells measured by real-time cell microelectronic sensing method. Cell index is 
expressed as an arbitrary unit and calculated from impedance measurements between cells and sensors. Data 
are presented as mean ± S.D., n = 4. TX, Triton X-100 at 10 mg/ml concentration. 
The toxicokinetic effects of Cremophors were monitored by real-time impedance 
measurement on epithelial and endothelial cells. Cell damage was specified as normalized 
cell index (CI), below the value of 0.5. After a transient increase, Cremophors time- and 
concentration-dependently decreased cell index values (Fig. 11). Cremophor RH40 at 1 
and 5 mg/ml concentrations did not induce cellular toxicity (Fig. 11a), while only 1 mg/ml 
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concentration of Cremophor EL was non-toxic for epithelial cells after 24 hours (Fig. 11b). 
Ten and 50 mg/ml concentrations of Cremophor RH40 increased the impedance in the first 
8-10 hours, than a gradual decrease could be observed and cell toxicity was measured after 
23 or 15 hours, respectively, (Fig. 11a). The effect of Cremophor EL was similar to RH40 
on epithelial cells, but the impedance drop and cell death were faster (Fig. 11b). 
Cremophors changed the cell index in concentration and time dependent manner on 
hCMEC/D3 endothelial cells (Fig. 11c-d). No decrease compared to control was observer 
at 1 hour treatment, but after 2 hours the surfactants significantly reduced the CI of 
endothelial cells. The 0.1 mg/ml concentrations lowered the impedance without toxic 
effects, but higher concentrations damaged the endothelial cells. 
 
 
Figure 12. Fluorescent staining of cell nuclei and tight junction membrane protein claudin-4 in Caco-2 epithelial 
cells after 1 and 24-hour treatments with Cremophors. Blue color: cell nuclei of living cells; red color: dead cells; 
green color: claudin immunostaining. Asterisk: holes formed between cells, fragmentation or loss of junctional 
immunostaining; arrows: changes in claudin immunostaining of cell membranes; CR, Cremophor RH40; CE, 
Cremophor EL; TX, Triton X-100. Bar = 10 µm. 
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The toxicity of Cremophors was also examined by fluorescent cell nuclei staining 
of epithelial and endothelial cells after 1-h and 24-h treatments. In Caco-2 epithelial 
cells no difference in nucleus staining was noticed after a 1-hour treatment with 
Cremophors (Fig. 12). Changes in claudin-4 staining could be detected already at 1-
hour treatment, disappearance or weak immunostaining at cell junctions, irregular 
membrane or cytoplasmic staining patterns were observed (Fig. 12). Incubation for 
24 hours with Cremophors at 1 mg/ml concentration did not kill epithelial cells, but 
claudin-4 immunostaining became irregular and its membrane localization became 
disturbed. Both epithelial viability and monolayer integrity were seriously impaired at 
10-50 mg/ml concentrations at 24 hour treatment. Cremophor EL enhanced cell 
detachment. 
 
 
Figure 13. Fluorescent staining of cell nuclei and tight junction membrane protein claudin-5 in primary rat brain 
vascular endothelial cells after 1 and 24-hour treatment with Cremophors. Blue color: cell nuclei of living cells; 
red color: dead cells; green color: claudin immunostaining. Asterisk: holes formed between cells, fragmentation 
or loss of junctional immunostaining; arrows: changes in claudin immunostaining of cell membranes; 
CR, Cremophor RH40; CE, Cremophor EL; TX, Triton X-100. Bar=30 µm. 
Short treatment with surfactants (1-50 mg/ml) did not result in endothelial cell 
death, as demonstrated by the blue cell nuclei (Fig. 13). Treatment with Cremophors 
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from 10 mg/ml for 24 hours or Triton-X 100 led to red staining of cell nuclei indicating 
membrane damage and toxicity (Fig. 13). Immunostaining for claudin-5 endothelial TJ 
protein was changed by all investigated concentrations of Cremophors at 1-h 
incubation. In contrast to control cells where a typical continuous belt -like staining was 
seen holes appeared between cells indicating barrier damage. Uneven pericellular 
claudin-5 staining with thickening and zipper-like pattern was also observed (Fig. 13). 
After 24-hour disappearance and disorganization of the junctional staining was 
observed. Cremophors at the highest concentrations of 10 and 50 mg/ml induced cell 
detachment and cell death.  
 
 
Figure 14. Toxicity of P-1695, M-1695, D-1216 sucrose fatty acid esters (10-3000 µg/ml) and Tween 80, 
Cremophor RH40 reference absorption enhancers (10-3000 µg/ml) on human Caco-2 intestinal epithelial cells 
measured by (a) MTT dye conversion and (b) LDH release methods. MTT values were compared to non-treated 
group (100 % viability). For LDH measurement values were compared to the Triton-X 100 treated group (100 % 
toxicity). Data are presented as mean ± S.D., n = 6; statistical analysis: ANOVA followed by Dunnett test; 
statistically significant differences (P < 0.05) were detected in the control group compared to the values 
measured in a: P-1695 group; b: M-1695 group; c: D-1216 group; e: Cremophor RH40 group. 
The effect of sucrose esters and reference non-ionic surfactants, Tween 80 and 
Cremophor RH40 on cell viability was also investigated and compared by colorimetric 
assays on Caco-2 intestinal epithelial cells. Treatment of Caco-2 cells with sucrose esters 
time- and concentration-dependently decreased the MTT dye conversion indicating 
reduced cell viability (Fig. 14 and Table 4). P-1695 palmitate and M-1695 myristate 
esters significantly reduced metabolic activity of Caco-2 cells at concentrations higher 
than 30 or 60 µg/ml, respectively, and caused cell death above 200 µg/ml (Fig. 14a). D-
1216 laurate ester was the least toxic among the investigated sucrose esters, the 
100 µg/ml concentration did not decrease epithelial cell viability, but 200 to 600 µg/ml 
concentrations reduced MTT conversion in epithelial cells after 1 hour. The reference 
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surfactants showed lower toxicity on epithelial cells. Tween 80 or Cremophor RH40 at 
3,000 µg/ml concentration did not reduce cell viability of epithelial cells for 1  hour 
(Fig. 14a). The highest concentration of Cremophor RH40 increased MTT dye 
conversion in Caco-2 cells. Similar viability results to MTT test were obtained by 
measurements of LDH enzyme release indicating plasma membrane damage. The non-
toxic concentrations for all sucrose esters were the same with both cell viability methods. 
Cell death was observed after 1-hour treatment with sucrose esters (>300 µg/ml), but 
Tween 80 or Cremophor RH40 did not increase the enzyme release at any tested 
concentrations (Fig. 14b). 
The concentrations of surfactants causing 50 % or complete cell death (TC 50 and 
TC 100) at 24 hours were lower than for the 1-hour treatments (Table 4). The non-toxic 
concentrations of P-1695, M-1695 and D-1216 were about 20, 20 and 100 µg/ml, 
respectively, by both assays. The toxic concentrations of reference absorption enhancers 
were more than one order of magnitude higher than that of sucrose esters. The TC 0 
values for Tween 80 were calculated as 473 µg/ml (MTT test) and 1068 µg/ml (LDH 
assay). The non-toxic concentrations of Cremophor RH40 on Caco-2 cells for 24 h were 
30,000 µg/ml and 2067 µg/ml determined by MTT test and LDH assay, respectively 
(Table 4). 
 
Absorption enhancers MTT dye conversion LDH enzyme release 
 
TC 0 
(µg/ml) 
TC 50 
(µg/ml) 
TC 100 
(µg/ml) 
TC 0 
(µg/ml) 
TC 50 
(µg/ml) 
TC 100 
(µg/ml) 
P-1695 19 49 128 20 72 260 
M-1695 18 62 211 20 61 189 
D-1216 99 189 360 92 162 283 
Tween 80 473 1073 2432 1068 1229 1621 
Cremophor RH40 30900 33884 n.a. 2067 11810 44668 
Table 4. Toxicity of P-1695, M-1695, D-1216 sucrose fatty acid esters and Tween 80, Cremophor RH40 
reference absorption enhancers on human Caco-2 intestinal epithelial cells was measured by MTT dye 
conversion and LDH release methods after 24 hours of incubations. The MTT values were compared to non-
treated group (100 % viability). For LDH measurement groups were compared to the Triton-X 100 treated group 
(100 % toxicity). TC 0, non toxic concentration; TC 50, caused 50 % toxicity, TC 100, 100 % cell death; n.a., not 
applicable. 
Based on the results of the toxicity tests for 1 hour, the following concentrations were 
considered as safe for treatments and applied in further experiments on Caco-2 epithelial 
cells: P-1695 30 µg/ml, M-1695 60 µg/ml, D-1216 100 µg/ml. For reference surfactants, 
Tween 80 and Cremophor RH40 the non-toxic and clinically relevant 1000 µg/ml 
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concentration was selected for further treatments (Kiss et al., 2013; Weis et al., 1994; Mercke 
Odeberg et al., 2003). 
3.2. Effects of sucrose esters and reference surfactants on the electrical resistance and 
impedance of epithelial cell layers  
Non-toxic concentrations of sucrose esters but not of reference surfactants 
increased the ionic permeability across Caco-2 monolayers monitored by impedance and 
TEER measurements (Fig. 15). Sucrose esters reduced the impedance of epithelial cell 
layers measured by RTCA SP (Fig. 15a). The impedance decreased rapidly from the 
baseline of 125 Ω to 90 Ω within 30 minutes by P-1695 (30 µg/ml) and D-1216 
(100 µg/ml) treatments. M-1695 (60 µg/ml) also significantly reduced the impedance of 
Caco-2 layers. Slight decrease but no significant change was caused by Tween 80 or 
Cremophor RH40. In accordance with the impedance measurements P-1695, M-1695 and 
D-1216 reduced the resistance of the cell layers to 25 %, 55 % and 62 % as compared to 
control at 1-hour treatment, but no change was observed for reference surfactants 
(Fig. 15b). 
 
 
Figure 15. Effects of P-1695 (30 µg/ml), M-1695 (60 µg/ml), D-1216 (100 µg/ml) sucrose fatty acid esters 
and Tween 80 (1000 µg/ml), Cremophor RH40 (1000 µg/ml) reference absorption enhancers on the 
impedance (a), and transepithelial electrical resistance (b) on Caco-2 epithelial cell layers. Data are 
presented as mean ± S.D., n = 4; statistical analysis: ANOVA followed by Dunnett test. Impedance 
measurement (a): statistically significant differences were detected after treatment with P-1695 (# P < 0.05, 
### P < 0.001); M-1695 (* P < 0.05, ** P < 0.01); D-1216 (+ P < 0.05, +++ P < 0.001) compared to the 
control group. TEER measurements (b): statistically significant differences were detected in sucrose ester 
treated groups (*** P < 0.001) compared to control. Abbreviations: C, control; P, P-1695; M, M-1695; D, D-
1216; Tw, Tween 80; CR, Cremophor RH40. 
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3.3. Effects of surfactants on epithelial cell layer permeability for drugs and fluorescein  
The permeability of hydrophilic atenolol was low (0.17 × 10
-6
 cm/s) across Caco-2 
cells and all surfactants significantly enhanced the penetration of atenolol across cell layers 
(Table 5). The Papp of passive lipophilic drugs antipyrine (80.67 × 10
-6
 cm/s) and caffeine 
(87.59 × 10
-6
 cm/s) was high and the absorption enhancers did not increase it (Table 5). 
The average apparent permeability coefficient of fluorescein was also low (AB: 
0.36 x 10
-6
 cm/s; BA: 1.82 x 10
-6
 cm/s), but higher in the BA direction (BA/AB ratio: 
5.1) (Fig. 16a), indicating active efflux transport in accordance with literature data on 
MRP2 mediated efflux of fluorescein (Legen et al., 2004). Using previously selected 
non-toxic concentrations for each surfactant, all investigated compounds caused 
significant increase in fluorescein flux in AB direction across Caco-2 layers after 1 and 
2-hour treatments (Fig. 16a and Appendix, Pub. III, Fig. S1). M-1695 myristate 
(60 µg/ml) and D-1216 laurate (100 µg/ml) sucrose esters highly increased the flux of 
fluorescein at 1 and 2-hour application (Fig. 16a). The elevation in fluorescein 
permeability caused by P-1695 sucrose ester (30 µg/ml) was smaller, but also significant 
(Fig. 16a). Tween 80 (1000 µg/ml) enhanced three fold the flux of fluorescein, while 
Cremophor RH40 at similar concentration elevated the dye permeability to 211 %. Only 
myristate sucrose ester, Tween 80, and Cremophor RH40 enhanced significantly the 
fluorescein penetration in the opposite direction (BA). A lag time was observed in the 
penetration enhancing effect of all surfactants based on clearance data of fluorescein in 
both directions in Caco-2 cells (Appendix, Pub. III, Fig. S1a-b). 
 
 
Passive 
hydrophilic 
Passive lipophilic 
 Atenolol Caffeine Antipyrine 
P-1695 
30µg/ml 
1.46 ± 0.02 *** 1.01 ± 0.01 0.95 ± 0.06 
M-1695 
60µg/ml 
2.37 ± 0.63 *** 0.99 ± 0.01 1.00 ± 0.02 
D-1216 
100µg/ml 
1.58 ± 0.08 *** 0.98 ± 0.03 0.99 ± 0.03 
Tween 80 
1000µg/ml 
2.11 ± 0.02 *** 1.06 ± 0.02 1.00 ± 0.02 
Cremophor RH40 
1000µg/ml 
1.20 ± 0.15 *** 1.00 ± 0.03 0.98 ± 0.01 
Table 5. Fold changes in the apparent permeability coefficients of atenolol, caffeine and antipyrine measured on 
confluent human Caco-2 intestinal epithelial cell layers after 1-hour treatment with P-1695, M-1695, D-1216 
sucrose fatty acid esters and Tween 80, Cremophor RH40 reference absorption enhancers. Data are presented 
as mean ± S.D., n = 3; statistical analysis: ANOVA followed by Dunnett test; *** P < 0.001, all concentrations 
were compared to control. 
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Sucrose esters and reference absorption enhancers were also tested at 30, 60, and 
100 µg/ml concentrrations for 1 hour (Fig. 16b-d). The effect of sucrose esters on 
fluorescein permeability was concentration dependent (Fig. 16b-d). At 30 µg/ml 
concentration P-1695 and M-1695 sucrose esters, but not the other surfactants (Fig. 16b), 
at 60 µg/ml concentration both M-1695 myristate and D-1216 laurate sucrose esters 
increased the permeability of the dye (Fig. 16c). D-1216 (100 µg/ml) raised the 
fluorescein flux two fold compared to control (Fig. 16d). In contrast to sucrose esters 
reference absorption enhancers in the concentration range of 30-100 µg/ml did not 
increase the permeability of fluorescein (Fig. 16b-d). 
 
 
Figure 16. The effect of sucrose esters and reference absorption enhancers on the apparent permeability 
coefficients of fluorescein on confluent Caco-2 cell layers applied in different (a) and same (b-d) 
concentrations. Treatment concentrations: (a) P-1695 (30 µg/ml), M-1695 (60 µg/ml), D-1216 (100 µg/ml), 
Tween 80 (1000 µg/ml), Cremophor RH40 (1000 µg/ml); (b) 30 µg/ml; (c) 60 µg/ml; (d) 100 µg/ml. Data are 
presented as mean ± S.D., n = 3; statistical analysis: two-way ANOVA followed by Bonferroni test (a) or 
ANOVA followed by Dunnett test (b-d); * P < 0.05, *** P < 0.001, all groups were compared to their 
respective control. Abbreviations: AB, apical to basal direction; BA, basal to apical direction; Papp, apparent 
permeability coefficient; C, control; P, P-1695; M, M-1695; D, D-1216; Tw, Tween 80; CR, 
Cremophor RH40. 
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3.4. Effects of sucrose esters and reference surfactants on epithelial intercellular 
junctions 
Claudin-1 transmembrane TJ protein, ZO-1 cytoplasmic junctional linker protein, 
and β -catenin adherens junction protein all appeared at the cell-cell borders in a 
continuous, belt-like manner. Treatments with sucrose esters or reference surfactants for 
1 hour did not affect the gross morphology of cells or intercellular junctions assessed by 
these immunostainings (Fig. 17a). No rupture of the junctions or fragmentation of the 
pericellular immunostaining was seen.  
F-actin structure was investigated in different regions of epithelial cells  (Fig. 17a). 
At the level of TJs the cortical actin ring was sharply delineated in the control cells 
mimicking tight junction protein immunostainings. Following treatments with sucrose 
esters and reference absorption enhancers this F-actin staining near the TJ region became 
wider and more blurred compared to control images. At the apical part of the cells the 
structure of microvilli was well shown by F-actin staining, which was preserved in all 
treatment groups (Appendix, Pub. III, Fig. S3) At the basal part of cells staining of F-
actin revealed long filaments organized in bunches (Appendix, Pub. III, Fig. S3). This 
filamentous organization was less observed in the treatment groups, except for P-1695. 
Cytochalasin D, which inhibits actin polymerization changed the F-actin staining: dot-
like aggregations appeared in the actin ring at the level of tight junctions and in the basal 
area (Appendix, Pub. III, Fig. S3). Triton X-100 surfactant disrupted the plasma 
membrane and the structure of the microvilli at apical surface (Appendix, Pub. III, Fig. 
S3). The junctional actin ring was mostly preserved, but aggregations were observed in 
the junctional and basal areas. 
The ultrastructure of TJs between Caco-2 cells was preserved in all treatment 
groups (Fig. 17b). No morphological change was seen by electron microscopy in the 
structure of apical microvilli, TJs, desmosomes, or interdigitations of adjacent epithelial 
cells. No open Tjs were observed in the control or treatment groups by checking 140 
electron micrographs (19-28 images/treatment group). 
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Figure 17. Effect of surfactants on cellular and junctional morphology, fluorescent immunostainings and electron 
microscopy. (a) Immunostaining for tight and adherens junction membrane proteins claudin-1, ZO-1 and β-
catenin and fluorescent staining for F-actin microfilaments in human Caco-2 intestinal epithelial cells after 1 hour 
treatment with sucrose esters and reference absorption enhancers. Bar for claudin-1, ZO-1 and β-catenin is 
20 µm and for F-actin is 15 µm. (b) Transmission electron microscopy at cell-cell connections after 1 hour 
treatment with sucrose esters and reference absorption enhancers; bar = 400 nm. Applied concentrations: P-
1695, 30 µg/ml; M-1695, 60 µg/ml; D-1216, 100 µg/ml; Tween 80, 1000 µg/ml; Cremophor RH40, 1000 µg/ml. 
Abbreviations: C, control; P, P-1695; M, M-1695; D, D-1216; Tw, Tween 80; CR, Cremophor RH40; ZO-1, 
zonula occludens protein-1; arrow: tight junction; AJ: adherens junction; DE: desmosome; ID: interdigitation. 
 32 
3.5. Effects of sucrose esters and reference surfactants on epithelial cell membranes 
The membrane fluidity of living epithelial cells was determined by the measurement of 
fluorescence anisotropy of the cationic membrane probe TMA-DPH (Fig. 18). The anisotropy 
slightly decreased from 0.293 ± 0.002 to 0.286 ± 0.001 in vehicle-treated Caco-2 cells after 
20 minutes. The membrane fluidizer benzyl alcohol quickly and greatly reduced the 
anisotropy: TMA-DPH fluorescence anisotropy fell to 90.2 % compared to control after 
3 minutes. Sucrose esters fluidized the plasma membrane of Caco-2 cells at all applied 
concentrations (Fig. 18a). A U-shaped dose-response curve was observed for all sucrose esters. 
The biggest change in the anisotropy compared to the control group was measured at 10 µg/ml 
of P-1695 (92.0 %), 30 µg/ml of M-1695 (91.9 %) and 60 µg/ml of D-1216 (96.1 %). At 
higher concentrations higher anisotropy was observed, indicating reduced membrane fluidity. 
 
 
Figure 18. The effect on plasma membrane fluidity of (a) sucrose esters, (b) reference absorption enhancers 
and benzyl alcohol measured by TMA-DPH fluorescence anisotropy on living Caco-2 cell suspensions. The 
anisotropy values in control cells were between 0.293 ± 0.002 and 0.286 ± 0.002 during the observation, and 
control value was considered as 100 %. Data are presented as mean ± S.D., n = 6; statistical analysis: two way 
ANOVA followed by Bonferroni posttest; *** P < 0.001, all groups were compared to control. Applied 
concentrations of sucrose esters: 1, 10, 30, 60, 100 µg/ml; treatment concentrations of reference surfactants: 1, 
10, 100, 1000 µg/ml. Benzyl alcohol was used at 30 mM concentration. Abbreviations: P, P-1695; M, M-1695; D, 
D-1216; Tw, Tween 80; CR, Cremophor RH40; BA, benzyl alcohol. 
The reference absorption enhancers at 1 µg/ml concentration did not alter significantly 
membrane fluidity in contrast to sucrose esters (Fig. 18b). Tween 80 at 10 µg/ml was also 
ineffective, but at 100 µg/ml and higher concentrations statistically significantly fluidized 
the plasma membrane of epithelial cells with lowest anisotropy at 1000 µg/ml (94.2 %). 
Cremophor RH40 was the most effective at 10 µg/ml concentration (94.0 %). Higher 
concentrations of the reference surfactants were also less effective to reduce membrane 
anisotropy. 
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3.6. Effects of sucrose esters and reference surfactants on efflux pump activity 
Efflux transporter activity in Caco-2 cells was measured by the cellular uptake of 
calcein AM, the cellular uptake and bidirectional transport of rhodamine 123, a ligand of P-gp and 
BCRP (Schinkel et al., 2003), and bidirectional permeability of vinblastine (Fig. 19). Co-
administration of surfactants and rhodamine 123 resulted in statistically significant increase in the 
uptake of rhodamine (Fig. 19a). M-1695 and Tween 80 caused the highest, six-fold accumulation 
of the marker molecule compared to control. Co-administration of sucrose esters and calcein AM 
significantly elevated the uptake of the ligand (200-245 %) (Fig. 19b). Co-treatment with 
Tween 80 (1000 µg/ml) also significantly increased the cellular accumulation of calcein AM. In 
contrast to rhodamine 123 uptake, Cremophor RH40 had no effect on calcein AM uptake 
(Fig. 19b). Verapamil (100 µM) and cyclosporin A (10 µM) significantly raised the level of both 
ligands in Caco-2 cells (Fig. 19a-b). 
 
 
Figure 19. The effects of absorption enhancers on efflux pump activity measured by ligand accumulation and 
permeability studies. The accumulation of (a) rhodamine 123, and (b) calcein AM was determined in co-treatment with 
sucrose esters, reference absorption enhancers, inhibitors verapamil and cyclosporine A on Caco-2 cells. The effects 
of surfactants on the apparent permeability coefficients of (c) rhodamine 123 and (d) vinblastine in two directions were 
measured on Caco-2 cell layers. Data are presented as mean ± S.D., n = 3-6; statistical analysis: ANOVA followed by 
Dunnett test (a-b) or two-way ANOVA followed by Bonferroni test (c-d); * P < 0.05, ** P < 0.01, *** P < 0.001, all 
groups were compared to control. Applied concentrations: P-1695, 30 µg/ml; M-1695, 60 µg/ml; D-1216, 100 µg/ml; 
Tween 80, 1000 µg/ml; Cremophor RH40, 1000 µg/ml; verapamil, 100 µM; cyclosporine A, 10 µM. Abbreviations: 
Papp, apparent permeability coefficient; R123, Rhodamine 123; C, control; P, P-1695; M, M-1695; D, D-1216; Tw, 
Tween 80; CR, Cremophor RH40; Ver, verapamil; Cyc A, cyclosporine A. 
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Rhodamine 123 permeability in AB direction was significantly enhanced by both 
absorption enhancers and efflux pump inhibitors as compared to control group (0.82 ± 0.18 × 10
-
6
 cm/s) (Fig. 19c). Treatments with sucrose esters resulted in several fold elevated AB flux of the 
marker molecule as compared to reference surfactants or efflux pump inhibitors. The transport of 
rhodamine 123 in BA direction was unchanged by P-1695 and D-1216, but increased by M-
1695. In contrast, reference absorption enhancers and efflux pump inhibitors significantly 
decreased rhodamine 123 efflux transport (Fig. 19c). The permeability of vinblastine, a ligand of 
P-gp and MRP-2 efflux pumps (Hellinger et al., 2012), was measured in both directions in the 
absence (AB: 0.33 × 10
-6
 cm/s; BA: 52.45 × 10
-6
) or presence of surfactants (Fig. 19d). All 
treatments increased the flux of drug in AB direction by several fold, and M-1695 sucrose ester 
had the most pronounced enhancer effect. P-1695 palmitate and D-1216 laurate esters, and 
Cremophor also elevated vinblastine penetration in BA direction. Verapamil and cyclosporine A 
reduced the drug transport in BA direction, but Tween 80 did not. 
Surfactants were also tested on MES-SA/Dx5 cells overexpressing P-gp and the parental 
(P-gp negative) MES-SA cell line (Fig. 20). Cells with enhanced membrane permeability were 
gated out by TO-PRO3 staining, therefore in this assay only P-gp inhibition was detected. The 
calcein accumulation observed in the absence of P-gp in MES-SA cells was not influenced by 
treatments. Due to the high level expression of P-gp, MES-SA/Dx5 cells showed reduced calcein 
accumulation. The P-gp-inhibitor verapamil (100 µM) increased the fluorescent dye uptake to 
the level of the control cell line. Except for Tween 80, the surfactants did not influence the 
accumulation of calcein in this assay, indicating a lack of interaction with P-gp.  
 
 
Figure 20. Effect of surfactants on calcein AM accumulation in P-gp positive MES-SA/Dx5 and P-gp negative MES-SA 
cell lines. Cellular calcein AM fluorescence was determined after the treatments with vehicle (dark gray), verapamil 
(light gray), and surfactants (black) and is shown in histogram. Applied concentrations: P-1695, 30 µg/ml; M-1695, 
30 µg/ml; D-1216, 100 µg/ml; Tween 80, 100 µg/ml; Cremophor RH40, 1000 µg/ml; Verapamil, 100 µM. 
Abbreviations: C, control; M, M-1695; P, P-1695; D, D-1216; Tw, Tween 80; CR, Cremophor RH40; Ver, verapamil. 
The assay was repeated three times; the histograms show data from a representative experiment. 
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4. DISCUSSION 
The use of absorption enhancers is important for improving drug bioavailability. The 
effects of pharmaceutical excipients may substantially differ and thorough knowledge about 
absorption enhancers is needed to develop better drug formulations. In the present PhD work 
selected surface active agents with solubilizer and absorption enhancer properties were 
investigated on cell culture models. New data were obtained on the effects and toxicity of the 
well-known and clinically applied excipients, Cremophor RH40 and Cremophor EL using in 
vitro culture models of intestinal and vascular barriers. The effects of three water soluble 
sucrose esters, palmitate, myristate, and laurate were also tested on cellular toxicity, drug 
permeability, intercellular junction morphology, efflux pump activity and plasma membrane 
fluidity, giving a more complex and detailed view on their action on cultured intestinal 
epithelial cells than previous works and compared to reference surfactants Tween 80 and 
Cremophor RH40. 
4.1. Surfactants and cellular toxicity 
Due to their amphiphilic properties surfactants can easily interact with cell membranes, 
perturb or disrupt the lipid bilayer. This effect depending on applied concentration and 
treatment time can be reversible (Anderberg et al., 1992) but higher concentrations may thin 
or rupture plasma membranes, damage the microvilli in the apical surface of cells, and lead 
to leakage of intracellular proteins or cell death (Anderberg et al., 1992; Hamid et al., 2009; 
Sakai et al., 1998). These adverse effects can be reduced by choosing appropriate surfactants 
for drug formulation or by lowering their concentrations to safe levels. 
4.1.1. Comparison of the effects of Cremophor RH40 and EL on viability of intestinal 
epithelial and vascular endothelial cells 
The use of Cremophor EL in various dosage forms is accompanied by many adverse 
reactions (Gelderblom et al., 2001), and understanding the side-effects of Cremophor EL is 
essential for safety reasons. The toxicity of Cremophor RH40 is less well known and 
examined, but it is also important because of its application in oral solutions and soft gelatin 
capsules (Strickley, 2004). 
In our study the cytotoxicity of Cremophors was tested in epithelial and endothelial 
cells using concentrations corresponding to clinical administration. The concentrations of 
Cremophor RH40 and EL in oral formulations ranges from 25 to 405 and 2 to 600 mg, 
respectively (FDA database for Inactive Ingredients in Approved Drug Products). The 
maximal dose of Neoral, containing Cremophor RH40 is 15 mg/kg bodyweight/day in 2 
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equal doses, therefore Cremophor RH40 may reach 4.5 mg/ml or higher concentrations in 
the stomach. It should be considered that patients may take Cremophor containing drugs 
chronically, for months or years. Cremophor EL concentrations in the blood can reach 
5 mg/ml after infusions of Taxol or Sandimmun (Gelderblom et al., 2001) and this level can 
be maintained for 3-24 hours.  
Human intestinal epithelial cells were damaged by the Cremophors in concentration 
dependent manner. These results are in agreement with previous works indicating impairment 
of viability in Caco-2 cells treated with Cremophors (Karpf et al., 2006; Maroju et al., 2010). 
The kinetics of the toxicity of Cremophor RH40 and EL on human endothelial cells was also 
demonstrated in the present work. The clinically observed side-effects might be related to 
changes in the viability and monolayer integrity of endothelial cells exerted by Cremophors. 
An unexpected effect was seen in epithelial cells treated with surfactants using MTT 
assay and impedance measurement. The dye conversion and monolayer impedance were 
transiently increased in higher concentrations of both excipients. Such a change was also 
observed in endothelial cells, but it lasted only for one hour. MTT assay involves several 
cellular processes (Liu et al., 1997), which may be influenced by Cremophors. The increased 
MTT dye conversion may reflect higher metabolic activity or changes in endocytosis of dye 
and exocytosis of formazan crystals. Activation of different G protein-coupled receptors in 
various mammalian cells lead to changes in cell shape and attachment resulting in a transient 
increase in impedance values (Atienza et al., 2006). The effect of Cremophors on metabolic 
activity, or endocytosis, or G protein-coupled receptors in epithelial or endothelial cells may 
cause this phenomenon and further experiments are needed to reveal this interaction. 
Endothelial cells were more sensitive than epithelial cells for treatments with 
Cremophor RH40 and EL. Short term incubations with Cremophors resulted in changes only 
in endothelial but not in epithelial cells based on impedance measurement. Cremophors, 
similarly to other surfactants have a profound influence on cell membranes, disturb lipid 
bilayer (Hugger et al., 2002) or remove certain lipids from the membranes (Groot et al., 
2001). Differences in the membrane lipid composition and in lipid rafts (Dias et al., 1992; 
Héliès-Toussaint et al., 2006; Simons et al., 2000) of epithelial and endothelial cells may be 
related to our observations on the divergent effects of Chremophors on these cell types. 
Cremophor RH40 was less toxic than EL in cultured epithelial and endothelial cells. 
Our data are in agreement with findings on K-562 lymphoid cell line (Kristmundsdóttir et 
al., 2002). The reason of the differences in the toxicity of the Cremophors is unknown. 
Distinct characteristics in the molecular structures may be related to the observed results 
(Fig. 5). Cremophor EL contains a double bond, which is not present in Cremophor RH40. 
Double bonds are more reactive than single covalent bonds in general, and may result in 
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higher cytotoxic effect. The higher lipophilicity of EL (HLB:12-14) than RH40 (HLB: 16) 
may also cause higher perturbation in cell membranes, and this effect can be connected to 
the critical micellar concentration (Christiansen et al., 2010), which is lower in case of 
Cremophor EL than that of RH40. 
4.1.2. Effects of sucrose esters and reference surfactants on epithelial cellular viability 
Investigation of sucrose fatty acid esters on Caco-2 cells revealed that D-1216 laurate 
ester (carbon chain length: 12) was the least toxic, while myristate (carbon chain length: 14) 
and palmitate (carbon chain length: 16) esters had higher toxicity at both 1- and 24-hour 
treatments. Similar results were obtained by these sucrose esters in the previous work of the 
research group on RPMI 2650 human nasal epithelial cell line (Kürti et al, 2012). The same 
range of non-toxic concentrations were described for an unspecified sucrose monoester in 
Caco-2 cells (Mine et al., 2003), and for sucrose laurate, Tween 80 and Cremophor RH40 on 
MDCK dog kidney cells and two MDCK derived cell lines (Hanke et al., 2010). The toxic 
concentrations of the reference surfactants Tween 80 and Cremophor RH40 are at least one 
order of magnitude higher than that of sucrose esters in our studies and in the literature 
indicating that reference molecules have a safer toxicity profile on cultured cells than 
sucrose esters. 
In contrast to cell culture works sucrose esters did not damage palatal and buccal pork 
tissues (Ganem-Quintanar et al., 1998). Sucrose fatty acid esters are hydrolyzed by intestinal 
enzymes into sucrose and fatty acids in animal studies and their metabolites were not toxic 
(Berry et al., 1960; Noker et al., 1997; Shigeoka et al., 1984). In addition, sucrose esters are 
hydrolyzed under acidic or basic conditions (Christiansen et al., 2011; Okumura et al., 2011) 
and bacterial lipases can disintegrate them (Marciello et al., 2011). Tween 80, Cremophor 
RH40 and Cremophor EL are also degraded in the intestine or in the blood (Christiansen et 
al., 2010; van Tellingen et al., 1999), but the effects of the metabolites are unknown. A 
recent review drew the attention to the dangers of using surfactants as food additives because 
their permeability enhancing and efflux pump inhibitor properties may cause intestinal 
barrier dysfunction and increase the incidence of allergic and autoimmune diseases (Csáki, 
2011), but conclusive animal studies and human data are missing. Despite the results of cell 
culture tests and the hypothesized dangers of surfactants ingested as additives in large 
quantities from foodstuff, the animal studies suggest that the toxicity of sucrose esters might 
be lower, if any, when given orally in small quantities as excipients. However, further 
chronic toxicity experiments are needed to prove the safety of sucrose esters as potential oral 
excipients. 
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4.2. Non-ionic surfactants and drug absorption 
It is widely known that surface active agents can improve the absorption of drugs 
(Deli, 2009; Aungs, 2000 and 2012; Renukuntla et al., 2013) but the mechanisms are not 
fully explored. The present investigation aimed to reveal the pathways affected by the 
selected surfactants to induce absorption enhancement. Various methods were used to 
determine the effect of sucrose esters, Tween 80 and Cremophor RH40 on the para- and 
transcellular permeability of drugs and tracers. 
Sucrose esters decreased the resistance and impedance of epithelial cell layers 
reflecting elevated ion penetration through the paracellular and transcellular pathways, 
respectively. Resistance of Caco-2 cell layer also dropped after treatment with sucrose esters 
in other studies (Mine et al., 2003). Reference surfactants did not change TEER of Caco-2 
monolayers in the present experiments and in two independent studies (Takahashi et al., 
2002; Yu et al., 2011), indicating no paracellular barrier opening. The resistance and 
impedance measurements suggest that sucrose esters enhance ion permeability through para- 
and trancellular pathways. 
We described for the first time that sucrose esters elevated the flux of the hydrophilic 
drug atenolol through Caco-2 cell layers, indicating the absorption enhancer properties of 
these surfactants. The tested excipients significantly increased the penetration of fluorescein 
in a concentration dependent manner in the AB direction. Since treatments were applied 
apically, similarly to per os drug administration, moderate or no permeability enhancement 
was observed in the opposite direction. The absorption enhancing effects of sucrose esters 
(Szűts et al., 2012), especially laurate was demonstrated in several in vivo investigations 
(Ganem-Quintanar et al., 1998; Lerk et al., 1993; Nakada et al., 1988; Onishi et al., 2012). 
Tween 80 and Cremophor RH40 increased fluorescein permeability only in higher 
concentrations, therefore sucrose esters are more effective in small concentrations. Reference 
surfactants enhanced the permeability of all compounds, except the lipophilic model drugs 
caffeine and antipyrine. These class I compounds of the Biopharmaceutics Classification 
System are highly soluble and have high permeability (Wu et al., 2005), and the tested 
surfactants could not elevate further the already high permeability. Both Tween 80 and 
Cremophor RH40 are excipients in medicines (Tw: Fluxarix, Boostrix, Tubersol, Tripedia; 
CR: Neoral) and their penetration increasing effects in the present study are in agreement 
with literature data (Horvát et al., 2009; Kürti et al., 2012; Nerurkar et al., 1997; Rege et al., 
2001; Takahashi et al., 2002). 
Immunostaining of junctional proteins, fluorescent labeling of F-actin and transmission 
electron microscopy were used to visualize intercellular connections and demonstrate the 
integrity of the paracellular barrier. It was observed for the first time that sucrose esters, 
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Tween 80 and Cremophor RH40 did not cause any major change in the distribution of 
immunostaining for junctional proteins claudin-1, ZO-1 and β-catenin on Caco-2 cells at the 
applied concentrations. Surfactants slightly changed the organization of F-actin at the 
junctional region and basal part of the cells, but did not cause visible opening of the 
junctions. This F-actin redistribution can be linked to changes in the functional permeability 
of the junctions (Deli, 2009). Cytoskeletal F-actin changes caused by an undefined sucrose 
ester were also observed in Caco-2 cells (Mine et al., 2003). Surfactants did not change the 
morphology of TJs investigated by electron microscopy. No disruption of junctions or cell 
layers were observed by these morphological examinations confirming the safety of the 
selected surfactant concentrations and that sucrose esters do not cause visible damage of 
intercellular junctions. 
The effect of sucrose esters on cell membranes was suggested (Hanke et al., 2010), but 
it was not investigated in living cells yet. The selected sucrose esters fluidized the plasma 
membrane of Caco-2 cells at lower concentrations than reference absorption enhancers, and 
caused stronger TMA-DPH fluorescence anisotropy reduction than Tween 80 or 
Cremophor RH40. Sucrose esters containing longer fatty acid chain increased better the 
membrane fluidity at lower concentrations, indicating a correlation between the length of 
fatty acid chain and effect on membrane fluidity. The maximal fluidization concentrations 
did not coincide with the maximal permeability enhancer effect of the surfactants. Several 
factors influence the membrane permeability of cells, including the fluidity of lipid bilayers, 
plasma membrane thickness and elasticity, and pore formation in the lipid layer 
(Lichtenberger et al., 2006; Peetla et al., 2013). This study focused on membrane 
fluidization, but other changes in cell membrane properties could contribute to the observed 
penetration enhancer effects. Other studies confirmed that surfactants, including our 
reference excipients, increase the fluidity of cellular plasma membranes, which is linked to 
enhanced membrane permeability and changes in the activity of membrane transporters and 
efflux pumps (Aungst, 2000; Rege et al., 2002; Nerurkar et al., 1997). 
The resistance, impedance, permeability, morphology and membrane fluidity 
measurements indicate that several mechanisms are involved in the absorption enhancer 
effect of sucrose esters (Fig. 21). All the tested surfactants elevated plasma membrane 
fluidity, which can contribute to increased transcellular passage of molecules. Sucrose esters 
decreased both resistance and impedance indicating an effect on the function of intercellular 
junctions and cellular membranes, thus enhancing drug permeability through both the trans- 
and paracellular routes. Tween 80 and Cremophor RH40 changed neither the morphology of 
intercellular junctions, nor the resistance of cell layers, suggesting no effect on paracellular 
transport.  
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4.3. Non-ionic surfactants and efflux pumps 
Efflux transporters hinder drug delivery across biological barriers and blocking 
these pumps is considered as a way to increase drug penetration (Darby et al., 2011). 
Surfactants were described to inhibit uptake transporters (Engel et al., 2012) as well as 
efflux pumps (Bogman et al., 2003; Hugger et al., 2002). The effect of sucrose esters on 
efflux pumps is contradictory with studies describing inhibitory (Cornaire et al., 2004; 
Hanke et al., 2010) or no effect (Takaishi et al., 2006). In the present experiments 
sucrose esters, unlike inhibitors or reference surfactants, increased the permeability of 
vinblastine and rhodamine 123 in AB, but not in the other direction, suggesting no 
inhibitory effect on efflux pumps. Sucrose esters elevated rhodamine 123 and calcein 
AM accumulation in co-treatment, which may have suggested an inhibitory effect of 
efflux transporters. However, our experiments conducted on a model cell line expressing 
P-gp ruled out this possibility, as the sucrose esters did not influence the P-gp-mediated 
efflux in MES-SA/Dx5 cells. Takaishi et al. suggested that elevated daunomycine flux in 
Caco-2 cells caused by sucrose esters is due to permeabilization of the cellular 
membrane (Takaishi et al., 2006), but our work is the first to experimentally prove that 
enhanced permeability is unrelated to P-gp inhibition. 
Reference surfactants significantly increased the accumulation of rhodamine 123. 
The uptake of calcein AM in Caco-2 cells was increased by Tween 80 and efflux pump 
inhibitors, but not by Cremophor RH40. The difference in the rhodamine and calcein AM 
uptake assays may be explained by the different specificity of the dyes: rhodamine 123 is 
a ligand of P-gp and BCRP while calcein AM is a ligand of P-gp, MRP-1 and -2 (Hanke 
et al., 2010; Schinkel et al., 2003). Reference surfactants significantly increased the 
penetration of rhodamine 123 and vinblastine in AB direction, but reduced the 
permeability in the other direction only for rhodamine. Vinblastine is a ligand of both P-
gp and MRP-2 which may explain the difference. Calcein AM uptake in P-gp expressing 
MES-SA/Dx5 cells verified that Tween 80 is a P-gp inhibitor. Our data indicate an 
inhibitory effect of the reference surfactants on efflux pump activity (Fig. 21) in 
agreement with other studies on Tween 80 (Gelderblom et al., 2001; Cornaire et al., 
2004; Hanke et al., 2010; Nerurkar et al., 1997; Engel et al., 2012) and Cremophor RH40 
(Hanke et al., 2010; Yamagata et al., 2007). 
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4.4. Conclusion 
The effects of pharmaceutical excipients, Cremophor RH40 and EL on the viability of 
human intestinal epithelial and vascular endothelial cells were compared for the first time. 
Cremophor RH40 was less toxic than Cremophor EL in both cell types. Endothelial cells 
were more sensitive than intestinal epithelial cells to treatments with Cremophors. The 
observed changes in endothelial cells may be related to the side effects of Cremophor EL in 
vivo. 
 
 
Figure 21. How sucrose esters, Tween 80 and Cremophor RH40 enhance permeability in epithelial cells? 
Sucrose esters and reference absorption enhancers may increase the penetration of molecules in several ways. 
(i) Surfactants enhance the dissolution of molecules and change plasma membrane fluidity which contribute to 
enhanced delivery of agents. (ii) Tween 80, but not sucrose esters, inhibits P-glycoprotein. (iii) Sucrose esters 
may alter the function but not the visible morphology of cellular junctions, while reference molecules have no 
effect. Abbreviations: CR, Cremophor RH40; P-gp, P-glycoprotein; SE, sucrose esters; TJ, tight junction; Tw, 
Tween 80. 
Sucrose esters are increasingly used as inactive ingredients in pharmaceutical products. 
Our study on cultured epithelial cells confirmed, that sucrose esters are effective absorption 
enhancers for both hydrophilic drugs and efflux pump ligands. Sucrose esters enhance drug 
penetration by the trans- and paracellular routes, but do not inhibit P-glycoprotein (Fig. 21). 
It was demonstrated for the first time that sucrose esters fluidize the plasma membrane of 
epithelial cells in low concentrations. Reference surfactants Tween 80 and Cremophor RH40 
increase drug penetration by the transcellular pathway and inhibition of efflux pump activity 
and not by acting on intercellular junctions. Sucrose esters as oral excipients may act 
differently than the reference absorption enhancers, therefore further studies are needed to 
optimize oral dosage forms with these surfactants. 
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5. SUMMARY 
Surfactants used in pharmaceutical products have several advantageous properties; 
they improve drug absorption and dissolution, and protect active molecules. However, 
adverse effects are also observed during the application of different surface active agents 
which necessitates the investigation of registered surfactants and novel absorption enhancer 
candidates. 
Cremophor RH40 and EL are widely used excipients in oral and intravenous drug 
formulations. Studies indicate that Cremophors, especially EL, have toxic side effects, but 
few data are available on endothelial and epithelial cells which form biological barriers and 
are directly exposed to these molecules. In our investigation human intestinal epithelial and 
vascular endothelial cells were treated with Cremophor RH40 and EL in clinically relevant 
concentrations and their toxic effect was monitored by several methods. Cremophors caused 
concentration- and time-dependent damage in both epithelial and endothelial cells. 
Endothelial cells were more sensitive to surfactant treatment than epithelial cells, and 
Cremophor EL was more toxic than RH40 in both cell types. Our results support and 
complement the previously experimentally described toxic effects of Cremophor EL which 
may be related to the clinically recognized side-effects of medicines containing 
Cremophor EL. Sucrose fatty acid esters are increasingly investigated as novel excipients in 
pharmaceutical research and some of them are registered in Pharmacopoeias both in the 
European Union and in the United States. Several studies documented their advantageous 
properties but few data are available on their toxicity profile, mode of action and efficacy on 
intestinal epithelial models. Three water soluble sucrose esters, palmitate (P-1695), myristate 
(M-1695), laurate (D-1216), and two reference absorption enhancers, Tween 80 and 
Cremophor RH40 were tested on human Caco-2 intestinal epithelial cells. Sucrose esters in 
non-toxic concentrations significantly reduced resistance and impedance of cells, but not 
reference surfactants. All excipients increased permeability for drugs and fluidized plasma 
membrane, but did not visibly open tight junctions. Tween 80 but not sucrose esters inhibit 
P-glycoprotein. Our data indicate that in addition to their dissolution increasing properties 
sucrose esters can enhance drug permeability through both the transcellular and paracellular 
routes but this effect is unrelated to P-glycoprotein inhibition. 
The presented results demonstrate the differences between the cellular actions of 
various non-ionic surfactant excipients, which can be important for the development of new 
pharmaceutical formulations and drug delivery systems. 
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a b s t r a c t
This study focused on an investigation of the applicability of sucrose laurate as surfactant in solid dis-
persions. Although this surfactant has a US Drug Master File, it has not been used so far in internal
pharmaceutical products. High drug-loaded solid dispersion systems consisting of gemﬁbrozil as amodel
drug and PEG 6000 as a carrier, with or without sucrose laurate (D1216), were prepared by the melting
method. Cytotoxicity studies onCaco-2monolayer cellswere also performed, in order to gain information
on the applicability of D1216 in oral formulations. The results showed that the presence of the surface-
active agent did not affect the solid-state characteristics of the model drug signiﬁcantly. A markedly
improved dissolution of gemﬁbrozil from the ternary solid dispersion systems was observed as com-
pared with the binary solid dispersion systems. The optimum concentration range of the D1216 in the
formulations was determined to be 5–10%. The effective ﬁnal concentrations of D1216 in the dissolution
experiments proved to be non-toxic towards CaCo-2 cells. The results suggest the potential use of D1216
in innovative internal pharmaceutical formulations.
© 2011 Elsevier B.V. All rights reserved.
The poor water solubility of drug substances and their low
rates of dissolution in the aqueous gastrointestinal ﬂuids often lead
to insufﬁcient bioavailability, and this remains a problem to the
pharmaceutical industry. Solid dispersions of hydrophobic drugs
in water-soluble carriers have attracted considerable interest as a
means of improving dissolution behaviour, and hence enhancing
bioavailability. Water-soluble carriers such as high-molecular-
weight polyethylene glycols (PEGs) and polyvinylpyrrolidones
(PVPs) have been most commonly used for solid dispersions
(Bikiaris et al., 2005; Craig and Newton, 1991; Leuner and
Dressman, 2000; Saharan et al., 2009; Serajuddin, 1999). The use
of surfactants with solubilizing properties, such as polysorbates,
poloxamers, Gelucires (polyethylene glycol glycerides), sodium
lauryl sulfate or vitamin E TPGS have also attracted consider-
able interest recently (Dehghan and Jafar, 2006; Jagdale et al.,
2010; Liu and Wang, 2007; Mura et al., 1999; Okonogi and
Puttipipatkhachorn, 2006; Owusu-Ababio et al., 1998; Sethia and
Squillante, 2002; Vasconcelos et al., 2007). As described in the
review by Vasconcelos et al. (2007), the third-generation solid
dispersion systems contain a surfactant carrier, or a mixture of
amorphous polymers and surfactants as carriers. These third-
generation solid dispersions are intended to achieve the highest
degree of bioavailability for poorly soluble drugs. The inclusion
∗ Corresponding author. Tel.: +36 6254 5572; fax: +36 6254 5571.
E-mail address: revesz@pharm.u-szeged.hu (P. Szabó-Révész).
of surfactants in the solid dispersions may help to avoid drug
recrystallization and to stabilize the systems (Vasconcelos et al.,
2007).
Sucrose esters (SEs) are widely used in the food and cosmet-
ics industries, and there has recently been great interest in their
applicability indifferent pharmaceutical ﬁelds. They arebiodegrad-
able, natural, non-ionic surface-active agents consisting of sucrose
as hydrophilic moiety and fatty acids as lipophilic groups (Abd-
Elbary et al., 2008; Csóka et al., 2007; GanemQuintanar et al., 1998;
Okamoto et al., 2005; Otomo, 2009; Ntawukulilyayo et al., 1993;
Shibata et al., 2002).
In an earlier study we investigated, the structure and ther-
mal behaviour of SE in order to predict their applicability in hot
melt technology (Szu˝ts et al., 2007). Our results revealed that SEs
are semicrystalline carriers, with both amorphous and crystalline
regions. During the preparation of solid dispersions, the drugs are
built into the amorphous phases of the SEs (Szu˝ts et al., 2008). In
melt technology,mainly the lipophilic SEsmay be suggested as car-
riers. They display characteristic melting, whereas SEs with high
or moderate HLB values only soften during heating (Szu˝ts et al.,
2007). It has also been found that hydrophilic SEs exhibit gelling
behaviour at body temperatures, which can inﬂuence the drug
release (Szu˝ts et al., 2010a,b). In view of these results, the appli-
cability of hydrophilic SEs alone as carriers in hot melt technology
is not suggested. Dispersion or dissolution of the drugs in the soft-
ened SEs is difﬁcult, and a high amount of swelling SEs can reduce
the rate of dissolution of a drug.
0378-5173/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.ijpharm.2011.03.033
Author's personal copy
108 A. Szu˝ts et al. / International Journal of Pharmaceutics 410 (2011) 107–110
The aim of the present study was to evaluate the applicabil-
ity of hydrophilic sucrose ester as surfactant in third-generation
solid dispersion systems together with a polymer. As carrier, the
commonly used PEG 6000 was chosen, with which the hydrophilic
(HLB=16) sucrose laurate showed the best miscibility among
the evaluated sucrose esters (sucrose-stearate, -palmitate and -
laurate). Although this surfactant has a US Drug Master File, it
has so far not been used in internal pharmaceutical products. In
this work, studies on the cytotoxicity of sucrose laurate on Caco-2
monolayer cells were also performed, in order to gain information
on its availability in oral formulations.
Gemﬁbrozil (GEM), a poorly water-soluble (29.1g/ml at
pH=6.2±0.1) model drug, was supplied by TEVA (Hungary).
PEG 6000, the carrier used in our experiments, was from Hun-
garopharma (Hungary). Sucrose laurate D1216 (HLB=16) was
kindly provided by Harke Pharma GmbH (Germany).
During the sample production, 40% w/w of GEM was always
applied. In the case of the binary systems, PEG 6000 was heated
at 70 ◦C in a sand bath and, after melting, the appropriate amount
of GEM was added. In dispersions incorporating surfactant (1%, 5%,
10%or 15%w/w), D1216was dissolved in themelted carrier prior to
the addition of GEM. The molten mixture was stirred manually for
15min, to achieve homogeneous dispersion of the drug. The melts
were quickly cooled to−10 ◦C in a freezer, afterwhich the solidiﬁed
samples were pulverized in a mortar and sieved to 200m.
The physical states of the GEM in the different samples were
evaluated by XRPD with a Miniﬂex II X-ray Diffractometer (Rigaku
Co. Tokyo, Japan), where the tube anodewas Cuwith K=1.5405 ´˚A.
Patterns were collected with a tube voltage of 30kV and a tube
current of 15mA in step scan mode (4◦/min). The instrument was
calibrated by using Si.
The release of the model drug was studied by using Phar-
matest equipment (Hainburg, Germany) at a paddle speed of
100 rpm. 100ml artiﬁcial enteric juice with a pH of 6.8 (±0.05)
at 37 ◦C (±0.5 ◦C) was used. The concentration of GEM was
determined spectrophotometrically at 276nm (Unicam UV/vis
spectrophotometer). The dissolution experiments were conducted
in triplicate.
The statistical test ANOVA was used to compare the results of
dissolution data. The difference between samples was deemed sta-
tistically signiﬁcant if the 95% conﬁdence intervals for the means
did not overlap (p<0.05).
Theeffect ofD1216on living cellswas testedbyusing thehuman
colon carcinomacell lineCaCo-2 (ATCC,USA), amodel of the intesti-
nal epithelium (Breemen and Li, 2005). Cells were grown in Eagle’s
minimal essential medium (MEM, Invitrogen) supplemented with
15% foetal bovine serum (Lonza, Switzerland) and 1% Na-pyruvate
(Sigma, Hungary). Conﬂuent monolayers were obtained in 96-well
plates (Orange Scientiﬁc, Belgium)3days after cell seeding. For tox-
icity experiments, Dulbecco’s Modiﬁed Eagle’s medium (DMEM)
without phenol red was used as assay medium. Two different cyto-
toxicity tests were performed. The lactate dehydrogenase (LDH)
assaydetects cell damage anddeathbymeasuring the release of the
cytoplasmic enzyme LDH from cells due to plasma membrane dis-
ruption. The LDH levels in culture medium were determined with a
commercially available kit (Cytotoxicity Detection Kit LDH, Roche,
Switzerland). An increase in the number of dead or membrane-
damaged cells results in an increase in LDH activity in the cell-free
culture supernatant. Cytotoxicity was calculated as a percentage of
the total LDH release from cells treated with 1% Triton X-100 as
detergent. The MTT test measures cell viability, because only living
and metabolically active cells can convert the yellow tetrazolium
salt (MTT, Sigma M5655) into insoluble purple formazan crystals.
The extent of dye conversion was determined spectrophotometri-
cally by measuring the absorbance at 570nm. In the MTT assay, a
Fig. 1. X-ray power diffraction data of pure materials and solid dispersion systems.
decrease in dye reduction correlates to the cell damage. Viability
was calculated as a percentage of the number of untreated con-
trol cells. All experiments were repeated at least three times; the
number of parallel wells for each treatment and time point varied
between 4 and 8.
An earlier study revealed that the hydrophilic sucrose stearate
and sucrose palmitate do not melt during heating, but only soften
(Szu˝ts et al., 2007). In consequence of this thermal behaviour, the
distribution of a drug in their melts is difﬁcult, and can result
in an inhomogeneous product. Hence, in the present study, the
applicability of sucrose laurate as a surfactant was examined in
a third-generation solid dispersion system. The solid dispersions
were prepared by the melting method, containing GEM as model
drug and PEG 6000 as carrier, with or without D1216 as surfactant.
In the ternary solid dispersion systems, when D1216 was used up
to 15%, a homogeneous melt could be formed.
Intact GEM and PEG 6000 displayed identical sharp XRPD peaks
at various values of 2, while the X-ray pattern of D1216 exhib-
ited an amorphous, broad halo (Fig. 1). In order to determine the
crystallinity degree of drug in solid dispersions, the intensity of
the most characteristic peak of GEM (intensity: 7767 at 2 =12.06)
was evaluated in the various systems. The XRPD pattern of GEM
binary solid dispersions demonstrated the diffraction peak of the
crystalline drug. This suggested that GEM existed in the crystalline
state in the solid dispersion system. However, the intensity of the
peaks of crystalline GEM in the solid dispersions was signiﬁcantly
lower than that of the intact drug, indicating a lower degree of
crystallinity of GEM in the binary solid dispersion system (inten-
Fig. 2. Dissolution curves of GEM and solid dispersion systems containing various
concentrations (0, 1, 5, 10 and 15%) of D1216 as surfactant.
Author's personal copy
A. Szu˝ts et al. / International Journal of Pharmaceutics 410 (2011) 107–110 109
Fig. 3. Cytotoxicity measurements on various concentrations of D1216 on Caco-2 epithelial cells by LDH release after treatment for 1h with D1216, and MTT dye conversion
following treatment for 4h (means± SD, n=8–4).
sity: 2500 at 2 =11.52). As the drug was highly loaded into the
solid dispersion, some of the GEM molecules were molecularly dis-
persed, and a higher amount of GEMexisted in the crystalline state.
The XRPD patterns of the ternary solid dispersions were similar to
those of the binary system (intensities of the most characteristic
peak of ternary systems: 2070 at 2 =11.64 (GEM-PEG-D1216 40-
55-5), 1950 at 2 =11.56 (GEM-PEG-D1216 40-50-10) and 2452 at
2 =11.52 (GEM-PEG-D1216 40-45-15) (Fig. 1). The incorporation
of D1216 up to 15% had no effect on the XRPD pattern of GEM in
the solid dispersion system.
Fig. 2 illustrates that the D1216 in samples resulted in signif-
icantly higher GEM release than that of started GEM. For the 1%
D1216-containing solid dispersion, the drug release was similar
(p>0.05) that to form the binary solid dispersion system, whereas
5% SE resulted in signiﬁcantly faster release. In this case, 90% of the
GEM had dissolved after 10min. With increasing content of D1216,
the dissolution rate increased further. 100% GEM release could be
attainedafter10minon theuseof10%D1216 (Fig. 2). Increaseof the
D1216 concentration from 10% to 15% did not result in signiﬁcantly
faster release. Accordingly, 5–10% D1216 seems to be optimum for
solid dispersions of GEM.
PEGs have beenused extensively as carriers for solid dispersions
due to their favourable solution properties, low melting points and
low toxicity. Thanks to these characteristics, they are approved by
the FDA for internal consumption.
Besides improving dissolution, surfactants can also enhance
absorption, thereby increasing the bioavailibility of poorly soluble
drugs (Deli, 2009). However, surfactants may be cytotoxic, which
can reduce their applicability in oral formulations (Dimitrijevic
et al., 2000; Ekelund et al., 2005; Kiss et al., 2010). In this study,
therefore, cytotoxicity measurements were made on the human
intestinal epithelial cell line Caco-2 in order to determine the max-
imum non-toxic concentration of D1216 as absorption enhancer.
The cytotoxicity of various concentrations of D1216 in LDH tests
is shown in Fig. 3. The concentration of D1216 that caused no
toxicity after 1h was below 200g/ml. In the MTT studies, the
durationof treatmentwas4h, and signiﬁcant toxicitywasobserved
when the D1216 concentration exceeded 100g/ml (Fig. 3). Above
600g/ml D1216, high toxicity occurred, resulting in the death of
Caco-2 cells (Fig. 3).
Our dissolution studies shown, that applying 5–10% D1216 was
optimum for GEM solid dispersions. In these formulations, the con-
centrations of D1216 in the dissolution media were 83.3g/ml
(5% D1216) and 166.7g/ml (10% D1216), proved to be non-toxic
towards Caco-2 cells.
The cytotoxicity studies demonstrated similarly as with other
surfactants, that, when the internal applicability of sucrose lau-
rate is under consideration, the possible risk of the local effect
of an increased concentration in the microenvironment of the
gastrointestinal tract must be taken into account. It should be
noted that the SEs are widely used in different food products,
and their acceptable daily intake was set as 40mg/kg/day. Sucrose
laurate was not considered in that evaluation, but the Euro-
pean Food Safety Authority (EFSA) recently pointed out that
the current speciﬁcations should be changed to include sucrose
laurate (EFSA, 2010).
It can be concluded that the applicability of sucrose laurate in
third-generation solid dispersions prepared by melt technology
may be regarded as a good technique with which to accelerate the
dissolution of poorly soluble drugs such as GEM. The presence of
1–15% surface-active agent did not appear to affect the solid-state
characteristics of GEM signiﬁcantly. The in vitro dissolution studies
shown, that applying 5–10% D1216 was optimum to improve GEM
release from solid dispersions. In these formulations, the concen-
trationsof sucrose laurate in thedissolutionmediawere83.3g/ml
(5% D1216) and 166.7g/ml (10% D1216), proved to be non-toxic
towards Caco-2 cells.
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ABSTRACT: Cremophor EL and RH40 are widely used excipients in oral and intravenous
drug formulations such as Taxol infusion to improve drug dissolution and absorption. Studies
indicate that Cremophors, especially EL, have toxic side effects, but few data are available on
endothelial and epithelial cells, which form biological barriers and are directly exposed to these
molecules. Human hCMEC/D3 brain endothelial and Caco-2 epithelial cells were treated with
Cremophor EL and RH40 in the 0.1–50 mg/mL concentration range. Cell toxicity was monitored
by real-time cell microelectronic sensing and verified by lactate dehydrogenase release and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, and morphological
methods. Cremophors caused dose- and time-dependent damage in both cell types. In endothe-
lial cells, 0.1 mg/mL and higher concentrations, in epithelial cells, concentrations of 5 mg/mL
and above were toxic, especially at longer incubations. Cell death was also proven by double
fluorescent staining of cell nuclei. Immunostaining for tight junction proteins claudin-4 and -5
showed barrier disruption in cells treated by surfactants at 24 h. In conclusion, Cremophor EL
and RH40 in concentrations corresponding to clinical doses caused endothelial and epithelial
toxicity. Endothelial cells were more sensitive to surfactant treatment than epithelial cells, and
Cremophor EL was more toxic than RH40 in both cell types. © 2013 Wiley Periodicals, Inc. and
the American Pharmacists Association J Pharm Sci 102:1173–1181, 2013
Keywords: absorption enhancer; Caco-2 cells; cell toxicity; Cremophor; endothelial; epithe-
lial; excipient; real-time cell microelectric sensing; surfactant; toxicokinetics
INTRODUCTION
Excipients are necessary for effective drug dissolu-
tion of pharmacons and their transport across biolog-
ical barriers.1 Nonionic surfactants such as Tweens
and Cremophor EL and RH40 are widely employed to
improve dissolution and delivery of drugs.2 Their tox-
icity profile is better than that of ionic surfactants,3
still during their application, side effects often occur.
Cremophor EL and RH40 are polyoxyethylene castor
oil derivatives used to formulate several drugs such
as antineoplastic paclitaxel, teniposide, and aplidine;
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immunomodulatory cyclosporine A; sedative di-
azepam; and antiretroviral lopinavir and ritonavir.2,4
Cremophor EL is applied in infusions, such as
Taxol, in oral capsules, such as Gengraf, as well as
in solutions.2 Adverse effects observed for Cremophor
EL4 include anaphylactoid hypersensitivity reactions
due to complement activation in human plasma.5 Ax-
onal demyelination6 and acute toxicity of the heart
and thymocytes7,8 were found in rats. Cremophor EL
induced damage in isolated human cancer cells9 and
human cell lines including Caco-2.10 These toxic ef-
fects are related to inhibition of cardiac mitochon-
drial respiration,11 cell membrane perturbation,4,12
and promotion of oxidative stress.8,13
Cremophor RH40 is used in microemulsions,14 in
self-emulsifying drug delivery systems,15 in buccoad-
hesive tablets,16 and in oral formulations, such as
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Neoral (Novartis, East Hanover, NJ). Recently, our
group has used Cremophor RH40 as an absorption en-
hancer in a nasal drug delivery system.17 Cremophor
RH40 is intensely investigated as a pharmaceutical
excipient, but there is little data on its toxicity profile
in cultured cells.18,19
Despite the use of Cremophors in clinically applied
drugs and in other formulations, their toxicity on bio-
logical barriers is not fully understood. To our knowl-
edge, there is no published information about the ef-
fect of Cremophors on brain endothelial cells, which
are directly affected during infusions of drugs and
may be related to their side effects.
The aim of the study was to evaluate the toxic ef-
fects of Cremophor EL and RH40 on culture models
of two important biological barriers. Brain endothe-
lial cells, applied in blood–brain barrier studies,20,21
and Caco-2 human intestinal epithelial cells, a model
of small intestinal barrier,22 were tested with Cre-
mophors in clinically relevant doses by real-time cell
microelectronic sensing (RT-CES), a new label-free
method, colorimetric end-point viability assays, and
cell morphology.
MATERIALS AND METHODS
Chemicals
All reagents were purchased from Sigma–Aldrich
Ltd., Budapest, Hungary, unless otherwise indicated.
Cell Culture
Human cell lines brain microvascular endothelial
hCMEC/D3 cells,23 intestinal epithelial Caco-2 cells
(ATCC HTB-37), and primary rat brain endothelial
cells were used. D3 cells were grown in Endothe-
lial Basal Medium-2 (EBM-2) containing Endothelial
Growth Medium-2 (EGM-2) BulletKit (Lonza, Basel,
Switzerland) supplemented with 2.5% fetal bovine
serum in a humidified 37◦C incubator with 5% CO2.
Caco-2 cells were grown in Eagle’s minimal essential
medium (Gibco, Invitrogen, Budapest, Hungary and
Carlsbad, CA) supplemented with 10% fetal bovine
serum, 1% sodium–pyruvate, and 50:g/mL gentam-
icin. Primary cultures of cerebral endothelial cells
were prepared from 2-week-old rats24 and used for
morphological studies. Cell lines were seeded in cul-
ture dishes at a density of 5 × 104 cells/cm2, and the
medium was changed every 2 days. Cells were sub-
cultured with 0.05% trypsin–EDTA solution. For RT-
CES, 96-well E-plates with built-in gold electrodes
(Roche, Budao¨rs, Hungary and Basel, Switzerland)
were used. Surfaces were coated with 0.05% rat-tail
collagen before cell seeding.
Treatment
Cremophor EL and RH40 (pharmaceutical grade;
BASF, Lampertheim, Germany) were tested at
0.1–50 mg/mL concentrations. Triton X-100 detergent
(10 mg/mL) was used in toxicity assays as a reference
compound to cause cell death.
Real-Time Cell Microelectronic Sensing
This technique dynamically monitors living cells.25,26
The xCELLigence system (Roche) utilizes impedance
derived from interaction between cells and electrodes
of E-plates to noninvasively quantify cell proliferation
and viability in real time. Culture medium (80:L)
was added to each well for background readings, then
80:L cell suspension was dispensed at the density
of 1 × 104 cells/well. Cells were grown until conflu-
ency. Impedance was measured every 2 min following
treatments. The cell index (CI) at each time point was
defined as (Rn − Rb)/15, where Rn is the cell-electrode
impedance of the well when it contains cells, and Rb
is the background impedance of the well with the
medium alone. The CIs were normalized to the latest
time point before the treatment of each group (CIn/
CIbefore treatment) or presented as percent of nontreated
control group [(CIn/CIaverage of control group) × 100]. CI
values reflect cell number, adherence, cell growth, and
health.25,26
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide Dye Reduction and Lactate Dehydrogenase
Release Assays
Colorimetric cell viability assays were performed as
described above.27 The yellow 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye is
converted by viable cells to purple formazan crystals;
therefore, decrease in dye conversion reflects cellular
damage. Human endothelial hCMEC/D3 and Caco-
2 epithelial cells were seeded on 96-well plates. The
confluent monolayers were treated with Cremophors
for 1 and 24 h. After treatment, cells were washed
with phosphate buffered saline (PBS) solution and in-
cubated with 0.5 mg/mL MTT solution in Dulbecco’s
modified Eagle’s medium for 3 h. Crystals were di-
luted with dimethyl sulfoxide, and dye conversion was
determined by absorbance measurement at 570 nm.
Nontreated control group was considered as 100%
viable.
Cell death and membrane damage were investi-
gated by detecting the release of intracellular lactate
dehydrogenase (LDH) enzyme to the phenol-red-free
culture medium. Cells in 96-well plates were treated
by Cremophors for 1 and 24 h. The LDH levels in cul-
ture supernatants were determined by a kit (Cyto-
toxicity Detection Kit LDH; Roche). Cytotoxicity was
calculated as a percentage of the total LDH release
from cells treated with 1% Triton X-100 detergent.
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Fluorescent Stainings
Cell viability was determined by double fluorescent
staining: bis-benzimide (Hoechst 33342 dye) labels all
cell nuclei, ethidium-homodimer-1 (Molecular Probes,
Eugene, OR) stains only dead cells. For morphological
examinations, primary brain endothelial cells with
tight barrier properties24 were used. Cells grown on
glass coverslips were treated with Cremophor EL
and RH40 for 1 and 24 h. Thirty minutes before
the end of the treatment, 10:M bis-benzimide and
ethidium-homodimer-1 were added to the cells. Cells
were fixed in 4% paraformaldehyde in PBS, perme-
abilized with 0.2% Triton X-100, and blocked with 3%
bovine serum albumin–PBS. Endothelial cells were
incubated with anti-claudin-5 antibody, and epithe-
lial cells were treated with claudin-4 antibody (Invit-
rogen) overnight. Incubation with Alexa-488 -labeled
secondary anti-rabbit antibody (Invitrogen) lasted for
1 h. Cells were washed three times with PBS between
each step. Coverslips were mounted in Gel Mount
(Biomeda, Foster City, CA). Claudin-5 stainings were
examined by a NikonEclipse TE2000 fluorescent mi-
croscope (Nikon, Tokyo, Japan) and photographed by
a Spot RT digital camera (Diagnostic Instruments,
Sterling Heights, MI). The claudin-4 immunostain-
ing of epithelial cells was detected by Leica SP5 con-
focal microscope (Leica Microsystems CMS GmbH,
Mannheim, Germany).
Statistical Analysis
All data presented are means ± SD. Values were com-
pared using analysis of variance followed by Dun-
nett’s test (GraphPad Prism 5.0; GraphPad Software
Inc., San Diego, CA). Changes were considered sta-
tistically significant at a p value of less than 0.05.
All experiments were repeated at least two times;
the number of parallel samples varied between four
and 12.
RESULTS
The toxicokinetic effects of Cremophors were tested
on endothelial and intestinal epithelial cells by RT-
CES. In the experiments, cell damage was specified as
normalized CI, below the value of 0.5. In hCMEC/D3
endothelial cells, both Cremophors showed dose- and
time-dependent toxicity. At 1-h after treatment, no
differences were observed as compared with control.
Statistically significant decrease was seen in CI val-
ues at the concentrations of 10 mg/mL (p < 0.05) and
50 mg/mL (p < 0.001) from 2 h (Figs. 1a and 1b). Cre-
mophors at all concentrations (0.1–5 mg/mL) resulted
in impedance drop in human endothelial cells. Con-
centrations of 5 mg/mL and above caused cell damage
after 2–3 h and cell death similar to the toxicity con-
trol after 12 h.
In Caco-2 epithelial cells treatment with 1 mg/mL,
Cremophors caused no decrease in CI compared with
control, indicating no cell damage (Figs. 1c and 1d). In
the first 10 h, Cremophor EL at 5 mg/mL increased the
impedance, then decreased it, and after 20 h of treat-
ment, epithelial cell death was detected. At 10–50 mg/
mL doses of the surfactant, rapid increase of the CI
was observed, followed by a drop of impedance and to-
tal loss of cell viability after 12 h. The kinetics of the
CI in epithelial cells treated with Cremophor RH40
was similar to Cremophor EL, but the impedance drop
and cell death were delayed (Fig. 1d).
The results of RT-CES measurement at 24-h treat-
ment point is shown in Figure 2. In endothelial cells,
both excipients significantly decreased the impedance
at all concentrations (Figs. 2a and 2b). The smallest
0.1 mg/mL concentration significantly reduced (p <
0.001), whereas higher doses drastically lowered the
CI of hCMEC/D3 cells, reflecting cell death.
In contrast, the two smallest concentrations of the
tensids caused no damage in Caco-2 cells even after
24-h treatment (Figs. 2c and 2d). The effects of the
two surfactants differed at the doses of 5–10 mg/mL.
Cremophor RH40 caused lower toxicity than EL. At
the highest concentration, Cremophors exerted cell
death in epithelial cells similarly to endothelial cells.
The real-time measurements were verified by col-
orimetric assays (Fig. 3). Endothelial cells were vi-
able, and no membrane leakage was detected at 1-
h application of surfactants (Fig. 3a). Cremophors
at 5–50 mg/mL doses increased cell viability. The
presence of excipients for 24 h did not cause cell
damage below 1 mg/mL doses, whereas 5 mg/mL and
higher concentrations killed the endothelial cells
(Fig. 3b). Caco-2 cells treated with Cremophors for
1 h did not show decrease of viability by MTT or
membrane damage by LDH assays (Fig. 3c). One
day treatment with 10 and 50 mg/mL surfactants
increased the leakage of LDH enzyme to cell su-
pernatant (Fig. 3d). Cell viability of epithelial cells
measured by MTT was only affected by 50 mg/mL
Cremophors. Significant differences were observed
between the effects of Cremophor EL and RH40 on ep-
ithelial cells by end-point assays as well. Cremophor
EL decreased cell viability and increased cell toxic-
ity more than RH40. These methods strengthen our
observation that brain endothelial cells are more sen-
sitive than intestinal epithelial cells: Cremophors kill
endothelial cells at 5 mg/mL concentration, whereas
in Caco-2 cells, 50 mg/mL doses caused a similar
effect.
The toxicity of Cremophors was also examined by
fluorescent cell nuclei staining of primary endothe-
lial cells and Caco-2 epithelial cells after 1- and 24-h
treatments (Fig. 4). Short treatment with surfactants
(1–50 mg/mL) did not result in endothelial cell death,
as demonstrated by the blue cell nuclei, in agreement
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Figure 1. Effects of Cremophor EL and RH40 (0.1–50 mg/mL) on human hCMEC/D3 endothe-
lial (a and b) and Caco-2 intestinal epithelial (c and d) cells measured by RT-CES method. CI
is expressed as an arbitrary unit and calculated from impedance measurements between cells
and sensors. Data are presented as mean ± SD, n = 4. TX, Triton X-100 at 10 mg/mL dose.
with data in Figures 1 and 3. Treatment with Cre-
mophors from 10 mg/mL for 24 h or Triton-X 100 led to
red staining of cell nuclei, indicating membrane dam-
age and toxicity (Fig. 4). Immunostaining for claudin-
5 endothelial tight junction protein was changed by all
investigated doses of Cremophors at 1-h incubation.
In contrast to control cells, where a typical continuous
belt-like staining was seen, holes appeared between
cells indicating barrier damage. Uneven pericellu-
lar claudin-5 staining with thickening and zipper-
like pattern was also observed (Fig. 4). After 24-h,
disappearance and disorganization of the junctional
staining were observed. Cremophors induced cell de-
tachment and cell death at the highest doses (10 and
50 mg/mL).
In Caco-2 epithelial cells, no difference in nu-
cleus staining was noticed after a 1-h treatment with
Cremophors (Fig. 4). Changes in claudin-4 staining
could already be detected at 1-h treatment; disap-
pearance or weak immunostaining at cell junctions
and irregular membrane or cytoplasmic staining pat-
terns were observed (Fig. 4). Incubation for 24 h with
Cremophors at 1 mg/mL did not kill epithelial cells,
but claudin-4 immunostaining became irregular and
its membrane localization became disturbed. Both
epithelial viability and monolayer integrity were
seriously impaired at 10–50 mg/mL concentrations
at 24-h treatment. Cremophor EL enhanced cell
detachment.
DISCUSSION
The use of Cremophor EL in various dosage forms
is accompanied by many adverse reactions.4 Under-
standing the side effects of Cremophor EL is impor-
tant for safety reasons. The toxicity of Cremophor
RH40 is less well known and examined, but it is also
important because of its application in oral solutions
and soft gelatin capsules.2
In our study, the cytotoxicity of Cremophors was
investigated in endothelial and epithelial cells us-
ing concentrations corresponding to clinically ad-
ministered doses. Cremophor EL concentrations in
blood can reach 5 mg/mL after infusions of Taxol or
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Figure 2. Effects of Cremophor EL and RH40 (0.1–50 mg/mL, 24 h) on human hCMEC/D3
endothelial (a and b) and Caco-2 epithelial (c and d) cells measured by RT-CES method. CI
is expressed as an arbitrary unit and calculated from impedance measurements between cells
and sensors. Data are presented as mean ± SD, n = 4; statistical analysis: ANOVA followed by
Dunnett test; ∗∗∗p < 0.001, all doses were compared with control. C, control; TX, Triton X-100
at 10 mg/mL dose.
Sandimmun.4 This level can be maintained for 3–24 h,
depending on the duration of the chemotherapeutic
treatment. Endothelial cells lining blood vessels are
exposed to high dose of this surfactant. The kinetics
of the toxicity of Cremophor EL and RH40 on human
endothelial cells was demonstrated for the first time.
The clinically observed side effects might be related
to changes in the viability and monolayer integrity of
endothelial cells exerted by Cremophors.
The dose of Cremophor EL and RH40 in oral for-
mulations ranges from 2 to 600 and 25 to 405 mg,
respectively.28 Neoral is a soft gelatin capsule of
cyclosporin A and contains the highest Cremophor
RH40 dose among oral formulations, 450 mg/capsule.
The maximal dose of Neoral is 15 mg/kg body weight/
day in two equal doses; therefore, Cremophor RH40
may reach 4.5 mg/mL or higher concentrations in
the stomach. It should be considered that patients
might take Cremophor-containing drugs chronically,
for months or years.
Human intestinal epithelial cells were also dam-
aged by the surfactants. These results are in agree-
ment with previous works indicating impairment of
viability in Caco-2 cells treated with Cremophors.10,18
An unexpected effect was seen in epithelial cells
treated with surfactants using RT-CES and MTT dye
conversion assay. The CI was transiently increased
in higher doses of both excipients. Such a change was
also observed in endothelial cells, but it lasted only for
1 h. Activation of different G-protein-coupled recep-
tors in various mammalian cells led to changes in the
cell shape and attachment resulting in a transient in-
crease in CI values.26 The increased MTT dye conver-
sion may reflect higher metabolic activity or changes
in endocytosis of dye and exocytosis of formazan crys-
tals. The effect of Cremophors on G-protein-coupled
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Figure 3. Effects of Cremophor EL and RH40 (0.1–50 mg/mL) on human hCMEC/D3 endothe-
lial cells (a and b) and Caco-2 epithelial (c and d) measured by MTT dye conversion and LDH
release methods. The MTT values were compared with nontreated group, which was defined as
100% viable. For LDH measurement, the Triton-X-100-treated group was considered as 100%
dead. Data are presented as mean ± SD, n = 5; statistical analysis: ANOVA followed by Dun-
nett test; ∗p < 0.05, ∗∗∗p < 0.001, all doses were compared with control. CrEL, Cremophor EL;
CrRH, Cremophor RH40.
receptors, metabolic activity, or endocytosis in epithe-
lial or endothelial cells cannot be excluded, and fur-
ther experiments are needed to reveal this interac-
tion.
Comparing the cell types, endothelial cells were
more sensitive than epithelial cells. Short-term in-
cubations with Cremophors resulted in changes only
in endothelial cells but not in epithelial cells. Cre-
mophors, similarly to other surfactants, have a pro-
found influence on cell membranes. Depending on
concentration, they disturb plasma membranes12
or remove certain lipids from the membranes.29
Lipid constitution varies between cell types,30 thus
Caco-2 cell membrane lipid composition31 differs
from endothelial ones,32 and lipid rafts are also
dissimilar.30 Differences in the membrane lipid com-
position and in lipid rafts of endothelial and ep-
ithelial cells may be related to our observations
on the divergent effects of Chremophors on these
cell types.
It should be noted that Cremophors modulate
efflux transporters including P-glycoprotein.12 The
Cremophor concentrations used in our study were
above the effective concentrations modulating P-
glycoprotein12 and higher than the critical micellar
concentrations33; therefore, we assume that the ma-
jor mode of action of Cremophors may be a direct ef-
fect on cell membranes, especially plasma membrane
lipids. Our results of LDH release indicate such direct
cell membrane damage.
On the basis of the results, Cremophor EL is more
toxic than RH40 in cultured endothelial and epithe-
lial cells. Our data are in agreement with the findings
on K-562 lymphoid cell line.19 The reason of the differ-
ences in the toxicity of the Cremophors is unknown.
Distinct characteristics in the molecular structures
may be related to the observed results.2 Cremophor
EL contains a double bond not present in Cremophor
RH40. Double bonds are more reactive than single co-
valent bonds in general, and may result in higher cy-
totoxic effect. In addition, the hydrophilic–lipophilic
balance value of Cremophor EL (12–14) is lower
than that of RH40 (14–16). The higher lipophilic-
ity of Cremophor EL may cause higher perturba-
tion in cell membranes. The critical micellar concen-
tration of Cremophor EL is also lower than that of
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Figure 4. Fluorescent staining of cell nuclei and tight junction membrane protein claudin-5
in primary rat brain endothelial cells and claudin-4 in Caco-2 epithelial cells after 1- and 24-h
treatment with Cremophors. Blue color, cell nuclei of living cells; red color, dead cells; green
color, claudin immunostaining. Asterix, holes formed between cells, fragmentation or loss of
junctional immunostaining; arrows, changes in claudin immunostaining of cell membranes;
CrEL, Cremophor EL; CrRH, Cremophor RH40; TX, Triton X-100. Endothelial cells, bar =
30:m; epithelial cells, bar = 10:m.
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RH40 that can contribute to higher damage at equal
concentrations.33
CONCLUSIONS
The effects of pharmaceutical excipients Cremophor
EL and RH40 on the viability of cultured human
endothelial and intestinal epithelial cells were com-
pared for the first time. Cremophor EL was more toxic
than Cremophor RH40 in both cell types. Endothelial
cells were more sensitive than intestinal epithelial
cells to treatments with Cremophors measured by RT-
CES, colorimetric viability assays, and morphological
methods. The observed changes in endothelial cells
may be related to the side effects of Cremophor EL
in vivo.
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ABSTRACT: Sucrose fatty acid esters are increasingly used as excipients in pharmaceutical products, but few data are available on
their toxicity profile, mode of action, and efficacy on intestinal epithelial models. Three water-soluble sucrose esters, palmitate (P-1695),
myristate (M-1695), laurate (D-1216), and two reference absorption enhancers, Tween 80 and Cremophor RH40, were tested on Caco-2
cells. Caco-2 monolayers formed a good barrier as reflected by high transepithelial resistance and positive immunostaining for junctional
proteins claudin-1, ZO-1, and -catenin. Sucrose esters in nontoxic concentrations significantly reduced resistance and impedance, and
increased permeability for atenolol, fluorescein, vinblastine, and rhodamine 123 in Caco-2 monolayers. No visible opening of the tight
junctions was induced by sucrose esters assessed by immunohistochemistry and electron microscopy, but some alterations were seen in
the structure of filamentous actin microfilaments. Sucrose esters fluidized the plasma membrane and enhanced the accumulation of efflux
transporter ligands rhodamine 123 and calcein AM in epithelial cells, but did not inhibit the P-glycoprotein (P-gp)-mediated calcein AM
accumulation in MES-SA/Dx5 cell line. These data indicate that in addition to their dissolution-increasing properties sucrose esters can
enhance drug permeability through both the transcellular and paracellular routes without inhibiting P-gp. C© 2014 Wiley Periodicals, Inc.
and the American Pharmacists Association J Pharm Sci
Keywords: absorption enhancer; Caco-2 cells; drug permeability; efflux pumps; epithelial; membrane fluidity; P-glycoprotein; sucrose
ester; tight junction; toxicity
INTRODUCTION
Drug delivery across biological barriers remains a great chal-
lenge in pharmaceutical research. One of the options to improve
permeability of low-penetrating active agents is the use of ab-
sorption enhancers.1 Nonionic surface-active agents, Tween 80,
an ethoxylated sorbitan and Cremophor RH40, a castor oil es-
ter, have been widely investigated and were demonstrated to
enhance the solubility or absorption of drugs.2,3 Clinically em-
ployed surfactants have advantageous properties as absorption
enhancers,4 but can also cause side effects.4–6 There is a need
for new, innovative absorption enhancers with more favorable
profile and fever drawbacks.
Sucrose fatty acid esters are nonionic surfactants that are
present naturally in plants and microorganisms.7 Food in-
dustry applies them as food emulsifiers and food additives.8,9
Because of low-skin irritation, excellent emulsification, and
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solubilizing properties, they are also used in cosmetics.10 Su-
crose esters are promising candidates for improving the solu-
bility and permeability of drugs as recently reviewed by Szu˝cs
and Szabo´-Re´ve´sz.11 Because of their excellent emulsifier and
surfactant properties, sucrose esters were tested for transder-
mal drug delivery in microemulsions and reversed vesicles.12–16
The use of sucrose esters for oral application was less studied.
Controlled release from matrix tablets containing sucrose es-
ters was demonstrated.17 Daunomycin accumulation was effec-
tively enhanced by sucrose esters in Caco-2 intestinal cells.18
In animal studies, sucrose esters improved the intestinal per-
meability of the polypeptide hormone calcitonin,19 lidocaine
hydrochloride,20 and cyclosporine A.21 The intestinal absorp-
tion of paracellular marker dextran was also enhanced by L-
1695 laurate ester treatment in rats.22 Although the paracel-
lular barrier in intestinal cells is regulated by intercellular
junctions,4 changes in tight or adherens junctions and transport
pathways following sucrose fatty acid ester treatments have
not been investigated yet. Sucrose esters were also described
to inhibit efflux pumps, mainly P-glycoprotein (P-gp, ABCB1)
in epithelial cells and in animal experiments.23,24 Although the
effect of sucrose esters on cell membranes was suggested,24 it
was not investigated in living cells.
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The human Caco-2 cell line is a widely used culture model
for intestinal drug absorption showing good correlation with in
vivo data, which structurally and functionally resembles small
intestinal epithelium.25–27 Cells are polarized, grow in mono-
layer, possess microvilli, form tight intercellular connections
by apical junctional complexes, and express solute carriers, and
efflux transporters such as P-gp, BCRP, or MRP-2.25,28,29
Our aim was to test the effects of three different sucrose
esters, namely, palmitate (P-1695), myristate (M-1695), and
laurate (D-1216) esters, on the viability, passive permeabil-
ity, junctional and cytoskeletal morphology, membrane fluidity,
and efflux pump activity of Caco-2 intestinal epithelial cells in
relation to reference absorption enhancers Tween 80 and Cre-
mophor RH40. The toxicity of surfactants was determined by
standard colorimetric end-point assays. The barrier properties
were tested by resistance and impedance measurements. To as-
sess passive and efflux transport across epithelial monolayers
atenolol, caffeine, antipyrine, vinblastine, fluorescein, and rho-
damine 123 were examined in the presence or absence of sur-
factants. Junctional morphology monitored by immunostaining
for claudin-1, zonula occludens protein-1 (ZO-1), $-catenin, and
transmission electron microscopy, and plasmamembrane fluid-
ity were investigated for the first time in sucrose ester-treated
Caco-2 cells. Filamentous actin (F-actin), a main cytoskeletal
protein contributing to normal organization of junctions was
also studied. The effect of the sucrose esters on efflux pump
activity was determined in Caco-2 cells; P-gp functionality was
measured on MES-SA and MES-SA/Dx5 cell lines.
MATERIALS AND METHODS
Materials
All reagents were purchased from Sigma–Aldrich Ltd. (Bu-
dapest, Hungary), unless otherwise indicated. Laurate sucrose
ester (D-1216) was of pharmaceutical grade; palmitate (P-1695)
and myristate (M-1695) sucrose esters were of analytical grade
(Mitsubishi Kagaku Foods Company, Tokyo, Japan). Tween 80
and Cremophor RH40 (BASF, Ludwigshafen am Rhein, Ger-
many) were of pharmaceutical grade. Supplementary Table S1
summarizes some of the properties of the surfactants employed
in the study.
Cell Culture
Human intestinal epithelial Caco-2 (ATCC catalog no. HTB-37,
USA) cell line was used in the experiments. To obtain a more
uniform morphology and higher efflux pump expression, cells
were treated with vinblastine (10 nM) for at least six passages
as described by Hellinger et al.26 Cells were grown in Eagle’s
MinimalEssentialMedium (Gibco, Life Technologies, Carlsbad,
California) supplemented with 10% fetal bovine serum (Lonza,
Basel, Switzerland), sodium-pyruvate (Gibco, Life Technolo-
gies), and 50 :g/mL gentamicin in a humidified 37◦C incubator
with 5% CO2. Cells were seeded in culture dishes at a den-
sity of 5 × 104 cells/cm2 and the medium was changed every
2 days. When cells reached approximately 80%–90% conflu-
ence in the dish, they were subcultured with 0.05% trypsin –
Ethylenediaminetetraacetic acid solution. For the cytotoxicity
assays, cells were cultured in 96-well plates (Orange Scien-
tific, Braine-l’Alleud, Belgium) and for real-time cell electronic
sensing (RT-CES), 96-well plates with gold electrodes (E-plate
96; ACEA Biosciences, San Diego, California) were used. For
electric resistance measurements and permeability studies,
Caco-2 cells were cultured on transwell inserts (polycarbon-
ate membrane, 0.4 :m pore size, 1.12 cm2 surface area; Corn-
ing Life Sciences, Tewksbury, Massachusetts). For staining of
nuclei, junctions and F-actin cells were grown on glass cov-
erslips (Menzel-Gla¨ser, Braunschweig, Germany). All surfaces
were coated with 0.05% rat tail collagen before cell seeding,
unless otherwise indicated.
Human uterine sarcoma lines MES-SA, and its doxorubicin-
selected derivative expressing high levels of P-gp (MES-
SA/Dx5) were used for testing P-gp functionality.30 Cells were
grown in Dulbecco’s modified Eagle medium (DMEM; Gibco,
Life Technologies) supplemented with 10% fetal bovine serum,
5 mM L-glutamine, and 50 unit/mL penicillin/streptomycin. To
maintain homogenous P-gp expression,MES-SA/Dx5 cells were
treated with 500 nM doxorubicin for at least two passages be-
fore the experiments.
Cell Viability Measurements
Treatment concentrations of sucrose esters P-1695, M-1695,
and D-1216 varied between 3 and 3000 :g/mL. The reference
absorption enhancers were used in 1–100,000 :g/mL concen-
trations. Treatment solutions were prepared in DMEM with-
out phenol red. Triton X-100 (10 mg/mL) was used as a toxicity
control.
(3-(4,5-Dimethyltiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) (MTT) dye conversion was used to measure cell metabolic
activity and viability. Caco-2 epithelial cells were cultured in
96-well plates for 3 days. Confluent cultures were treated for 1
or 24 h, washed with phosphate-buffered saline (PBS; pH 7.4)
and incubated with 0.5 mg/mL MTT solution for 3 h in a CO2
incubator. The amount of blue formazan crystals converted by
cells was dissolved in dimethyl sulfoxide and determined by
measuring absorbance at 595 nmwavelength with amicroplate
reader (Fluostar Optima; BMG Labtechnologies, Ortenberg,
Germany). Cell viability was calculated as percentage of dye
conversion by nontreated cells.
Lactate dehydrogenase (LDH) release, the indicator of cell
membrane damage, was determined from culture supernatants
by “Cytotoxicity detection kit (LDH)” (Roche, Basel, Switzer-
land). Caco-2 cells cultured in 96-well plates for 3 days were
treated for 1 or 24 h with absorption enhancers, and then 50 :L
samples from culture supernatants were incubated with equal
amounts of reaction mixture for 15 min. The enzyme reaction
was stopped by 0.1MHCl. Absorbancewasmeasured at awave-
length of 492 nm with a microplate reader (Fluostar Optima;
BMGLabtechnologies). Cell deathwas calculated as percentage
of the total LDH release from cells treated by 10 mg/mL Triton
X-100. The nontoxic concentrations (TC0), 50% toxic concen-
trations (TC50), and concentrations causing death in all cell
(TC100) were calculated from fitted curves (GraphPad Prism
5.0; GraphPad Software Inc., San Diego, California); equations
are shown in Supporting Information 1.
Measurement of Electrical Resistance and Impedance of Cell
Layers
Transepithelial electrical resistance (TEER) was measured by
an EVOM resistance meter using STX-2 electrodes (World Pre-
cision Instruments Inc., Sarasota, Florida) and expressed rela-
tive to the surface area ( × cm2). TEER represents the para-
cellular permeability of cell layers for ions. The TEER of Caco-2
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monolayers was 800 ± 138  × cm2 (mean ± SD; n = 158) af-
ter 3 weeks of culture. Resistance measurements were carried
out before and after permeability studies to check the barrier
integrity.
Impedance was measured at 10 kHz by RTCA SP instru-
ment (ACEA Biosciences) and reflects the permeability of cel-
lular membranes in confluent cultures.31,32 Impedance nonin-
vasively quantifies proliferation, viability, or permeability of
adherent cells in real time.6,33,34 E-plates with gold electrodes
were coated with 0.2% gelatine–PBS solution for 20 min at
37◦C. Culture medium (80 :L) was added to each well for back-
ground readings and then 80 :L cell suspension was dispensed
at the density of 6 × 103 cells/well. The cells were kept in
incubator at 37◦C for 48 h and monitored every 5 min. The
impedance at each time point was defined as Rn – Rb, where
Rn is the cell–electrode impedance of the well when it contains
cells and Rb is the background impedance of the well with the
medium alone. During treatments, cells impedance was mea-
sured every 2 min.
Permeability Study
The flux of the drugs caffeine, antipyrine, atenolol, vinblastine,
and fluorescent dyes fluorescein and rhodamine 123 across ep-
ithelial cell layers was determined in apical to basal (AB) di-
rection. The flux of vinblastine, fluorescein, and rhodamine 123
was alsomeasured in basal to apical (BA) direction. Caco-2 cells
were seeded onto transwell filter inserts, and the resistance of
the cell layers was checked twice aweek. After 21 dayswhen the
resistance was high and stable, the inserts were transferred to
12-well plates containing 1.5 mL Ringer–HEPES solution (150
mMNaCl, 6 mMNaHCO3, 5.2 mMKCl, 2.2 mMCaCl2, 0.2 mM
MgCl2, 2.8 mM D-glucose, 5 mM HEPES, pH 7.4) in the baso-
lateral compartments. In apical chambers, culture mediumwas
replaced by 500 :LRinger–HEPES-containing drugs ormarker
molecules with or without absorption enhancers. The drugs and
rhodamine 123 were used at 10 :M; fluorescein was adminis-
tered at 10 :g/mL concentration. Absorption enhancers were
applied in the apical compartment in the following concentra-
tions: Tween 80 and Cremophor RH40 at 30, 60, 100, and 1000
:g/mL; P-1695 and M-1695 at 30 and 60 :g/mL; and D-1216 at
30, 60, and 100 :g/mL. The plates were kept in a CO2 incuba-
tor on a rocking platform (100 rpm) for 1 h in case of atenolol,
caffeine, antipyrine, and rhodamine 123. For vinblastine and
fluorescein, 2-h permeability test was performed, and samples
were taken from the acceptor phase at both 1 and 2 h time
points. After the incubation, samples from the upper and lower
compartments were collected and the concentrations of fluo-
rescein and rhodamine 123 were determined by a fluorescent
microplate reader (Fluostar Optima; BMG Labtechnologies),
whereas drug concentrations were measured by HPLC, as de-
tailed below. The apparent permeability coefficients (Papp) in
AB and BA directions, and the clearance of the molecules were
calculated (Supporting Information Eqs. 3–7).
HPLC Analytical Procedures
Analytical measurements were performed on a Merck-Hitachi
LaChrom HPLC system equipped with UV and fluorescence
detector (Merck, Darmstadt, Germany). Antipyrine and vin-
blastine were determined by using Purospher C18e 125 ×
3mm2 (5 :m) column (Merck) operated at 0.5mL/min flow rate,
maintained at 40◦C. Mobile phase for antipyrine consisted of
40% methanol in 0.1 M ammonium acetate with isocratic elu-
tion. UV detection was at 250 nm wavelength. The calibration
curve showed a good linearity within the examined concentra-
tion range of 0.1–10 :M (r2 = 0.999). For vinblastine, elution
was applied to a mixture of 250 mL methanol, 200 mL 25 nM
ammonium acetate, and 3mL 10% trifluoroacetic acid. Vinblas-
tine was quantified at 275/360 nm excitation/emission wave-
lengths. The calibration curve was linear with an r2 = 0.998
in the range of 0.01–1 :M. Samples with higher than 1 :M
vinblastine concentration were 10× diluted in Ringer–HEPES
solution. HPLC measurement of caffeine was performed using
Purospher C18e 125 × 4 mm2 (5 :m) column (Merck) operated
at 0.8 mL/min flow rate, maintained at 35◦C. Mobile phase
was 15% methanol in 0.1 M ammonium acetate. UV detection
was at 275 nm. The r2 of the calibration curve was 0.999 in
the concentration range of 0.1–10 :M. Samples with atenolol
were injected onto a Gemini C18e 150 × 3 mm2 (5 :m) col-
umn (Phenomenex Inc., Aschaffenburg, Germany) operated at
35◦C and at an eluent flow rate of 0.5 mL/min. Elution was
applied to a mixture of 300 mL methanol, 400 mL 0.1 M am-
monium acetate, 20 mL 10% ammonium hydroxide, and 2 mL
0.1 M Na2–EDTA. Atenolol was quantified at 230/300 nm exci-
tation/emission wavelengths. The calibration curve was linear
with an r2 = 0.999 in the range of 0.01–1 :M. Samples with
higher than 1 :M atenolol concentration were diluted 10× in
Ringer–HEPES solution.
Fluorescent and Immunostainings
Morphology and cell–cell connections of Caco-2 cells were con-
firmed by immunostaining for claudin-1, zonula occludens pro-
tein 1 (ZO-1), and $-catenin. F-actin was stained by fluores-
cently labeled phalloidin, and cell nuclei by bis-benzimide dye
(Hoechst dye 33342). Cell layers were grown on glass cover-
slips and treated with absorption enhancers (P-1695 30 :g/mL,
M-1695 60 :g/mL, D-1216 100 :g/mL, and Tween 80 and Cre-
mophor RH40 1000 :g/mL) for 1 h. Cytochalasin D, an inhibitor
of actin polymerization, was applied at 2 :g/mL concentration.
After treatments, the cultures were washed twice in PBS and
fixed with 4% paraformaldehyde PBS for 30 min. Cells were
blocked with 3% bovine serum albumin in PBS and incubated
with primary antibodies anti-claudin-1, anti-ZO-1, and anti-$-
catenin (Gibco, Life Technologies) overnight. Incubation with
secondary antibody Cy3-labeled antirabbit IgG, Alexa Fluor
488 Phalloidin (Gibco, Life Technologies), and bis-benzimide
lasted for 1 h. Between and after incubations, cells were washed
three timeswith PBS. Coverslips weremounted by fluoromount
and staining was examined by a Leica SP5 confocal microscope
(Leica Microsystems GmbH, Wetzlar, Germany).
Electron Microscopy
Cells grown on culture inserts were treated with absorp-
tion enhancers (P-1695 30 :g/mL, M-1695 60 :g/mL, D-1216
100 :g/mL, and Tween 80 and Cremophor RH40 1000 :g/mL)
for 1 h. After treatments, cells were washed by PBS and fixed
with 3% paraformaldehyde containing 0.5% glutaraldehyde in
cacodylate buffer (pH 7.4) for 30 min at 4◦C. After washing
with the buffer several times, cells were postfixed in 1% OsO4
for 30 min. Following a rinse with distilled water, the cells
were dehydrated in graded ethanol and block stained with 1%
uranyl acetate in 50% ethanol for 1 h. After the last step of
dehydration, inserts were placed in the 1:1 mixture of ethanol
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and Taab 812 (Taab; Aldermaston, Berks, UK) for 30 min at
30◦C. Finally, the membranes of the culture inserts with the
cells were removed from their support and embedded in Taab
812. Polymerization was performed overnight at 60◦C. Ultra-
thin sections were cut perpendicularly for the membrane us-
ing a Leica UCT ultramicrotome (Leica Microsystems, Milton
Keynes, UK) and examined using a Hitachi 7100 transmission
electron microscope (Hitachi Ltd., Tokyo, Japan).
Measurement of Plasma Membrane Fluidity in Caco-2 Cells
Caco-2 cells were collected by trypsinization, washed twice, and
resuspended in PBS. The density of cells was set by absorbance
measurement at 360 nm to OD360 = 0.1 (Hewlett Packard
8452A Diode Array Spectrophotometer). Cells were labeled
with 0.2 :M TMA-DPH [1-(4-trimethylammoniumphenyl)-6-
phenyl-1,3,5-hexatriene; Molecular Probes, Life Technologies]
for 5 min. Fluorescence anisotropy wasmeasured on a T-format
fluorescence spectrometer (Quanta Master QM-1; Photon Tech-
nology International, Princeton, New Jersey). Excitation and
emission wavelengths were 360 and 430 nm, respectively (5-
nm slits). Cells were kept at 37◦C under stirring conditions.35,36
Anisotropy data were acquired in every second. After 5 min,
the lowest concentrations of treatment solutions were added
rapidly to the cell suspension and every 3 min the treatment
concentration was increased during anisotropy measurements.
Control cells received only vehicle. A strong membrane flu-
idizer, benzyl alcohol (30 mM) (Merck), was used as a positive
control in the experiments. The following treatment concentra-
tions were applied: 1, 10, 30, 60, and 100 :g/mL for sucrose
esters; and 1, 10, 100, and 1000 :g/mL for Tween 80 and Cre-
mophor RH40. The average of 50 anisotropy measurements in
the last 1 min of each treatment concentration was calculated
and compared with the anisotropy of the vehicle-treated cells
at the same time point.
Measurement of Efflux Pump Activity
The activity of efflux pumps was determined by cellular accu-
mulation of rhodamine 123 and calcein AM (Gibco, Life Tech-
nologies) in Caco-2 epithelial cells grown in 24-well plates for
2 days (seeding density: 105 cells/well). In the pretreatment
experiments, cells were incubated with surfactants P-1695
(30 :g/mL), M-1695 (60 :g/mL), D-1216 (100 :g/mL), Tween 80
(1000 :g/mL), Cremophor RH40 (1000 :g/mL) or efflux pump
inhibitors verapamil (100 :M), and cyclosporin A (10 :M) for
1 h, and then the cell layers were washed and incubated with
10 :M rhodamine 123 in Ringer–HEPES solution for another
1 h. In the cotreatment experiments, cells were preincubated
with Ringer–HEPES buffer for 20 min. Treatments with sur-
factants or efflux pump inhibitors were carried out in the pres-
ence of rhodamine 123 for 1 h. Following incubations, cells were
washed three times with ice-cold PBS and lysed with 0.1 M
NaOH in both types of experiments. Rhodamine 123 concen-
tration was determined by a fluorescent microplate reader (ex-
citation wavelength: 485 nm, emission wavelength: 520 nm;
Fluostar Optima; BMG Labtechnologies).
The calcein AM assay can be used for the measurement of
the activity of efflux transporters P-gp and multidrug resis-
tance protein-1 or -2 (MRP-1 and MRP-2).24,37 For calcein AM
assay, Caco-2 cells were seeded on 96-well plate (cell density:
7 × 104 cells/well) and grown for 24 h. In the pretreatment
experiments, cells were incubated for 1 h with surfactants or
efflux pump inhibitors. After the treatments, cells were washed
and the buffer solution was replaced with 1.25 :M calcein AM
in Ringer–HEPES, and the plate was immediately placed in
a microplate reader (Fluostar Optima; BMG Labtechnologies).
The fluorescence was measured at 5 min intervals for 1 h (ex-
citation wavelength: 485 nm; emission wavelength: 520 nm).
In the cotreatment experiments, cells were preincubated with
Ringer–HEPES for 20 min. Treatments with surfactants or ef-
flux pump inhibitors were performed in the presence of 1.25 :M
calcein AM. Fluorescence was immediately measured by a mi-
croplate reader at 5 min intervals for 1 h. The fluorescence
intensity was calculated as percentage of the control group.
To estimate the effect of sucrose esters on P-gp functional-
ity, calcein AM accumulation was measured in the presence
of the test substrates in MES-SA and MES-SA/Dx5 cells.38,39
Cells (2 × 105 cells/100 :L) were preincubated with vera-
pamil (100 :M), P-1695 (30 :g/mL), M-1695 (30 :g/mL), D-
1216 (100 :g/mL), Tween 80 (100 :g/mL), Cremophor RH40
(1000 :g/mL), or with solvent dimethyl sulfoxide (less than
0.1%) for 5 min at 37◦C. M-1695 and Tween 80 were applied in
lower concentrations because of different sensitivity of sarcoma
cells as compared with Caco-2 cells. Thereafter, 0.25 :M calcein
AM was added and the cells were incubated for 10 min at 37◦C.
Cellswere gated based onTO-PRO3positivity (Gibco, Life Tech-
nologies). Samples were measured by a FACSCaliburTM flow
cytometer (BD Biosciences, San Jose, California).
Statistical Analysis
All data presented are means ± SD. Values were compared us-
ing analysis of variance (ANOVA) followed by Dunnett’s test
(GraphPad Prism 5.0; GraphPad Software Inc., San Diego,
California). In case of fluorescein, vinblastine, and rhodamine
123 permeability and TMA-DPH anisotropy measurements,
two-way ANOVA followed by Bonferroni posttest was applied.
Changes were considered statistically significant at p < 0.05.
All experiments were repeated at least two times, and the num-
ber of parallel samples varied between 4 and 12.
RESULTS
Effect of Sucrose Esters on the Viability of Cultured Epithelial Cells
The treatment of Caco-2 cells with sucrose esters concentration
and time dependently decreased MTT dye conversion indicat-
ing reduced cell viability (Fig. 1; Table 1). P-1695 and M-1695
esters significantly reduced metabolic activity of Caco-2 cells at
concentrations higher than 30 or 60 :g/mL, respectively, and
caused cell death above 200 :g/mL (Fig. 1a). D-1216 laurate
ester was the least toxic among the investigated sucrose es-
ters; the 100-:g/mL concentration did not decrease epithelial
cell viability, but 200–600 :g/mL concentrations reduced MTT
conversion in epithelial cells after 1 h. The reference surfac-
tants showed lower toxicity on epithelial cells. Tween 80 or
Cremophor RH40 at 3000 :g/mL concentration did not reduce
cell viability of epithelial cells for 1 h (Fig. 1a). The highest
concentration of Cremophor RH40 increased MTT dye conver-
sion in Caco-2 cells. Similar viability results to MTT test were
obtained by measurements of LDH enzyme release indicating
plasma membrane damage. The nontoxic concentrations for all
sucrose esters were the same with both cell viability meth-
ods. Cell death was observed after 1-h treatment with sucrose
esters (>300 :g/mL), but Tween 80 or Cremophor RH40 did
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Figure 1. Toxicity of P-1695, M-1695, and D-1216 sucrose fatty acid
esters (10–3000 :g/mL) and Tween 80 and Cremophor RH40 reference
absorption enhancers (10–3000 :g/mL) on human Caco-2 intestinal
epithelial cells measured by (a) MTT dye conversion and (b) LDH re-
lease methods. The MTT values were compared with nontreated group
(100% viability). For LDH measurement, values were compared with
the Triton-X 100 treated group (100% toxicity). Data are presented as
mean ± SD, n = 6; statistical analysis: ANOVA followed by Dunnett
test; statistically significant differences (p < 0.05) were detected in
the control group as compared with the values measured in aP-1695,
bM-1695, cD-1216, and dCremophor RH40 groups.
not increase the enzyme release at any tested concentrations
(Fig. 1b). On the basis of the results of the toxicity tests for
1 h, the following concentrations were considered as safe for
treatments and applied in further experiments on Caco-2 ep-
ithelial cells: P-1695 30 :g/mL, M-1695 60 :g/mL, and D-1216
100 :g/mL. For reference surfactants, Tween 80 and Cre-
mophor RH40, the nontoxic and clinically relevant 1000 :g/mL
concentration, was selected for further treatments.6,40,41
The concentrations of surfactants causing 50% or complete
cell death (TC 50 andTC100) at 24 hwere lower than for the 1-h
treatments (Table 1). The nontoxic concentrations of P-1695,
M-1695, and D-1216 were about 20, 20, and 100 :g/mL, respec-
tively, by both assays. The toxic concentrations of reference
absorption enhancers were more than one order of magnitude
higher than that of sucrose esters. The TC 0 values for Tween
80 were calculated as 473 :g/mL (MTT test) and 1068 :g/mL
(LDH assay). The nontoxic concentrations of Cremophor RH40
on Caco-2 cells for 24 h were 30,000 and 2067 :g/mL deter-
mined by MTT test and LDH assay, respectively (Table 1).
Effect of Sucrose Esters on the Electrical Resistance and
Impedance of Epithelial Cell Layers
Nontoxic concentrations of sucrose esters but not of refer-
ence surfactants increased the ionic permeability across Caco-
2 monolayers monitored by impedance and TEER measure-
ments. Sucrose esters reduced the impedance of epithelial cell
layers measured by RTCA SP (Fig. 2a). The impedance de-
creased rapidly from the baseline of 125 to 90  within 30 min
by P-1695 (30 :g/mL) and D-1216 (100 :g/mL) treatments. M-
1695 (60 :g/mL) also significantly reduced the impedance of
Caco-2 layers. Slight decrease but no significant change was
caused by Tween 80 or Cremophor RH40. In accordance with
the impedance measurements, P-1695, M-1695, and D-1216 re-
duced the resistance of the cell layers to 25%, 55%, and 62%
as compared with control at 1-h treatment, but no change was
observed for reference surfactants (Fig. 2b).
Effect of Sucrose Esters on Caco-2 Permeability for Drugs and
Fluorescein
The permeability of hydrophilic atenolol (0.17 × 10−6 cm/s)
was low across Caco-2 cells and all surfactants significantly en-
hanced the penetration of atenolol across cell layers (Table 2).
The Papp of passive lipophilic drugs antipyrine (80.67 × 10−6
cm/s) and caffeine (87.59 × 10−6 cm/s) was high and the ab-
sorption enhancers did not increase it (Table 2).
The average apparent permeability coefficient of fluorescein
was also low (AB: 0.356 × 10−6 cm/s; BA: 1.82 × 10−6 cm/s),
but higher in the BA direction (BA/AB ratio: 5.1) (Fig. 2c), in-
dicating active efflux transport in accordance with literature
data on MRP2-mediated efflux of fluorescein.42 Using previ-
ously selected nontoxic concentrations for each surfactants, all
investigated compounds caused significant increase in fluores-
cein flux in AB direction across Caco-2 layers after 1 and 2-h
Table 1. Cellular Toxicity of Sucrose Esters and Reference Molecules
MTT Dye Conversion LDH Release
Absorption Enhancers TC 0 (:g/mL) TC 50 (:g/mL) TC 100 (:g/mL) TC 0 (:g/mL) TC 50 (:g/mL) TC 100 (:g/mL)
P-1695 19 49 128 20 72 260
M-1695 18 62 211 20 61 189
D-1216 99 189 360 92 162 283
Tween 80 473 1073 2432 1068 1229 1621
Cremophor RH40 30,900 33,884 n.a. 2067 11,810 44,668
Toxicity of P-1695, M-1695, and D-1216 sucrose fatty acid esters and reference absorption enhancers Tween 80 and Cremophor RH40 on human Caco-2 intestinal
epithelial cells was measured by MTT dye conversion and LDH release methods after 24 h of incubations. The MTT values were compared with nontreated group
(100% viability). For LDH, measurement groups were compared with the Triton-X 100-treated group (100% toxicity).
TC 0, nontoxic concentration; TC 50, caused 50% toxicity, TC 100, 100% cell death; n.a., not applicable.
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Figure 2. Effects of P-1695 (30 :g/mL), M-1695 (60 :g/mL), and D-
1216 (100 :g/mL) sucrose fatty acid esters and Tween 80 (1000 :g/mL)
and Cremophor RH40 (1000 :g/mL) reference absorption enhancers on
(a) the impedance, (b) TEER, and (c) fluorescein bidirectional perme-
ability on Caco-2 epithelial cells layer. Data are presented as mean ±
SD, n = 4; statistical analysis: ANOVA followed by Dunnett test (a and
b) or two-way ANOVA followed by Bonferroni test (c). Impedance mea-
surements (a): statistically significant differences were detected after
treatment with P-1695 (#p < 0.05, ###p < 0.001); M-1695 (*p < 0.05,
**p < 0.01); D-1216 (+p < 0.05, +++p < 0.001) as compared with the
control group. TEER measurements (b): statistically significant differ-
ences were detected in sucrose ester-treated groups (***p < 0.001) as
compared with control. Fluorescein permeability (c): treatment groups
were compared with their respective control in both directions (*p <
0.05, ***p < 0.001). Abbreviations: C, control; P, P-1695; M, M-1695; D,
D-1216; Tw, Tween 80; and CR, Cremophor RH40.
Table 2. Effect of Surfactants on Drug Permeability
Passive Hydrophilic Passive Lipophilic
Atenolol Caffeine Antipyrine
P-1695
(30 :g/mL)
1.46 ± 0.02*** 1.01 ± 0.01 0.95 ± 0.06
M-1695
(60 :g/mL)
2.37 ± 0.63*** 0.99 ± 0.01 1.00 ± 0.02
D-1216
(100 :g/mL)
1.58 ± 0.08*** 0.98 ± 0.03 0.99 ± 0.03
Tween 80
(1000 :g/mL)
2.11 ± 0.02*** 1.06 ± 0.02 1.00 ± 0.02
Cremophor RH40
(1000 :g/mL)
1.20 ± 0.15*** 1.00 ± 0.03 0.98 ± 0.01
Fold changes in the apparent permeability coefficients of atenolol, caffeine,
and antipyrine measured on confluent human Caco-2 intestinal epithelial cell
layers after 1 h treatment with P-1695, M-1695, and D-1216 sucrose fatty acid
esters and Tween 80 and Cremophor RH40 reference absorption enhancers.
Data are presented asmean± SD, n= 3; statistical analysis: ANOVA followed
by Dunnett test; ***p < 0.001, all concentrations were compared with control.
treatments (Fig. 2c and Supplementary Fig. S1). M-1695
(60 :g/mL) and D-1216 (100 :g/mL) sucrose esters highly in-
creased the flux of fluorescein at 1 and 2-h application (Fig. 2c).
The elevation in fluorescein permeability caused by P-1695 su-
crose ester (30 :g/mL) was smaller, but also significant (Fig. 2c).
Tween 80 (1000 :g/mL) enhanced threefold the flux of fluores-
cein, whereas Cremophor RH40 at similar concentration ele-
vated the dye permeability to 211%. Only M-1695 sucrose es-
ter, Tween 80, and Cremophor RH40 enhanced significantly
the fluorescein penetration in the opposite direction (BA). A
lag time was observed in the penetration-enhancing effect of
all surfactants based on clearance data of fluorescein in both
directions in Caco-2 cells (Supplementary Figs. S1a and S1b).
Sucrose esters and reference absorption enhancers were also
tested at 30, 60, and 100 :g/mL concentrations for 1 h (Supple-
mentary Figs. S2a-S2c). The effect of sucrose esters on fluores-
cein permeability was concentration dependent (Supplemen-
tary Figs. S2a-S2c). At 30 :g/mL concentration, P-1695 and
M-1695 sucrose esters, but not the other surfactants (Supple-
mentary Fig. S2a), and at 60 :g/mL concentration, bothM-1695
andD-1216 sucrose esters increased the permeability of the dye
(Supplementary Fig. S2b). D-1216 (100 :g/mL) raised the fluo-
rescein flux twofold as compared with control (Supplementary
Fig. S2c). In contrast with sucrose esters, reference absorp-
tion enhancers in the concentration range of 30–100 :g/mL did
not increase the permeability of fluorescein (Supplementary
Fig. S2).
Effects of Sucrose Esters on the Epithelial Intercellular Junctions
Claudin-1 transmembrane tight junction protein, ZO-1 cy-
toplasmic junctional linker protein, and $-catenin adherens
junction protein all appeared at the cell–cell borders in a
continuous, belt-likemanner. Treatmentswith sucrose esters or
reference surfactants for 1 h did not affect the grossmorphology
of cells or intercellular junctions assessed by these immunos-
tainings (Fig. 3a). No rupture of the junctions or fragmentation
of the pericellular immunostaining was seen.
Filamentous actin structure was investigated in different re-
gions of epithelial cells. At the level of TJs, the cortical actin
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Figure 3. Effect of surfactants on cellular and junctional morphology, fluorescent immunostainings, and electron microscopy. (a) Immunos-
taining for tight and adherens junction membrane proteins claudin-1, zonula occludens-1, and $-catenin and fluorescent staining for F-actin
microfilaments in human Caco-2 intestinal epithelial cells after 1 h treatment with sucrose esters and reference absorption enhancers. Bar
for claudin-1, ZO-1, and $-catenin is 20 :m and for F-actin is 15 :m. (b) Transmission electron microscopy at cell–cell connections after 1 h
treatment with sucrose esters and reference absorption enhancers; bar = 400 nm. Applied concentrations: P-1695, 30 :g/mL; M-1695, 60 :g/mL;
D-1216, 100 :g/mL; Tween 80, 1000 :g/mL; and Cremophor RH40, 1000 :g/mL. Abbreviations: C, control; P, P-1695; M, M-1695; D, D-1216;
Tw, Tween 80; CR, Cremophor RH40; ZO-1, zonula occludens protein-1; arrow: tight junction; AJ: adherens junction; DE: desmosome; and ID:
interdigitation.
ring was sharply delineated in the control cells mimicking TJ
protein immunostainings (Fig. 3a). Following treatments with
sucrose esters and reference absorption enhancers, this F-actin
staining near the TJ region became wider and more blurred
compared with control images. At the apical part of the cells,
the structure of microvilli was well shown by F-actin staining,
which was preserved in all treatment groups (Supplementary
Fig. S3). At the basal part of cells, staining of F-actin revealed
long filaments organized in bunches (Supplementary Fig. S3).
This filamentous organization was less observed in the treat-
ment groups, except for P-1695. Cytochalasin D, which inhibits
actin polymerization, changed the F-actin staining: dot-like ag-
gregations appeared in the actin ring at the level of TJ and
in the basal area (Supplementary Fig. S3). Triton X-100 sur-
factant disrupted the plasma membrane and the structure of
microvilli at the apical surface (Supplementary Fig. S3). The
junctional actin ring was mostly preserved, but aggregations
were observed in the junctional and basal areas.
The ultrastructure of TJs between Caco-2 cells was pre-
served in all treatment groups (Fig. 3b). No morphological
change was seen by electron microscopy in the structure of api-
cal microvilli, TJs, desmosomes, or interdigitations of adjacent
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Figure 4. The effect on plasma membrane fluidity of (a) sucrose es-
ters, (b) reference absorption enhancers, and benzyl alcohol measured
by TMA-DPHfluorescence anisotropy on living Caco-2 cell suspensions.
The anisotropy values in control cells were between 0.293 ± 0.002 and
0.286± 0.002 during the observation, and control value was considered
as 100%. Data are presented as mean ± SD, n = 6; statistical analysis:
two-way ANOVA followed by Bonferroni test; ***p < 0.001, all groups
were compared with control. Applied concentrations of sucrose esters:
1, 10, 30, and 60, 100 :g/mL; treatment concentrations of reference
surfactants: 1, 10, 100, and 1000 :g/mL. Benzyl alcohol was used at 30
mM concentration. Abbreviations: P, P-1695; M, M-1695; D, D-1216;
Tw, Tween 80; CR, Cremophor RH40; and BA, benzyl alcohol.
epithelial cells. No open TJs were observed in the control or
treatment groups by checking 140 electron micrographs (19–28
images/treatment group).
Effects of Sucrose Esters on Plasma Membrane Fluidity in
Caco-2 Cells
Themembrane fluidity of living epithelial cells was determined
by the measurement of fluorescence anisotropy of the cationic
membrane probe TMA-DPH (Fig. 4). The anisotropy slightly de-
creased from 0.293 ± 0.002 to 0.286 ± 0.001 in vehicle-treated
Caco-2 cells after 20 min. The membrane fluidizer benzyl al-
cohol quickly and greatly reduced the anisotropy: TMA-DPH
fluorescence anisotropy fell to 90.2% as compared with control
after 3 min. Sucrose esters fluidized the plasma membrane of
Caco-2 cells at all investigated concentrations (Fig. 4a). A U-
shaped dose–response curve was observed for all sucrose esters.
The biggest change in anisotropy as compared with the control
group was measured at 10 :g/mL of P-1695 (92.0%), 30 :g/mL
of M-1695 (91.9%) and 60 :g/mL of D-1216 (96.1%). At higher
concentrations, higher anisotropy was observed, indicating re-
duced membrane fluidity.
Reference absorption enhancers at 1 :g/mL concentration
did not alter significantly membrane fluidity, in contrast to
sucrose esters (Fig. 4b). Tween 80 at 10 :g/mL was also in-
effective, but at 100 :g/mL and higher concentrations, statisti-
cally significantly fluidized the plasma membrane of epithelial
cells with lowest anisotropy at 1000 :g/mL (94.2%). Cremophor
RH40was themost effective at 10 :g/mL concentration (94.0%).
Higher concentrations of reference surfactants were also less
effective to reduce membrane anisotropy.
Effect of Sucrose Esters on Efflux Pump Activity
Efflux transporter activity in Caco-2 cells was measured by the
cellular uptake of calcein AM, the cellular uptake and bidirec-
tional transport of rhodamine 123, a ligand of P-gp and BCRP,43
and bidirectional permeability of vinblastine (Fig. 5). Coadmin-
istration of surfactants and rhodamine 123 resulted in statisti-
cally significant increase in the uptake of rhodamine (Fig. 5a).
M-1695 and Tween 80 caused the highest, sixfold accumulation
of the marker molecule compared with control. Coadministra-
tion of sucrose esters and calcein AM significantly elevated
the uptake of the ligand (200%–245%) (Fig. 5b). Cotreatment
with Tween 80 (1000 :g/mL) also significantly increased the
cellular accumulation of calcein AM. In contrast to rhodamine
123 uptake, Cremophor RH40 had no effect on calcein AM up-
take (Fig. 5b). Verapamil (100 :M) and cyclosporin A (10 :M)
significantly raised the level of both ligands in Caco-2 cells
(Figs. 5a and 5b).
Pretreatment with sucrose esters did not change the accu-
mulation of rhodamine 123 in Caco-2 cells, but Tween 80 and
Cremophor RH40 raised slightly the dye uptake to 133% and
117%, respectively (Supplementary Fig. S4a). Pretreatment
with surfactants did not significantly increase the uptake of
calcein AM except for Tween 80 (113%) (Supplementary Fig.
S4b). Verapamil and cyclosporin A pretreatment increased both
rhodamine 123 and calcein AM accumulation in Caco-2 cells
(Supplementary Fig. S4).
Rhodamine 123 permeability in AB direction was signifi-
cantly enhanced by both absorption enhancers and efflux pump
inhibitors as compared with control group (0.82 ± 0.18 × 10−6
cm/s) (Fig. 5c). Treatments with sucrose esters resulted in sev-
eral fold elevated AB flux of the marker molecule as compared
with reference surfactants or efflux pump inhibitors. The trans-
port of rhodamine 123 inBAdirectionwas unchanged byP-1695
and D-1216, but increased by M-1695. In contrast, reference
absorption enhancers and efflux pump inhibitors significantly
decreased rhodamine 123 permeability (Fig. 5c).
The permeability of vinblastine, a ligand of P-gp and MRP2
efflux pumps,27 was measured in both directions in the absence
(AB: 0.33 × 10−6 cm/s; BA: 52.45 × 10−6) or the presence of
surfactants (Fig. 5d). All treatments increased the flux of drug
in AB direction by several fold, and M-1695 sucrose ester had
the most pronounced enhancer effect. P-1695 and D-1216 es-
ters, and Cremophor also elevated vinblastine penetration in
BA direction. Verapamil and cyclosporine A reduced the drug
transport in BA direction, but Tween 80 did not.
Surfactants were also tested on MES-SA/Dx5 cells overex-
pressing P-gp and the parental (P-gp negative) MES-SA cell
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Figure 5. The effects of absorption enhancers on efflux pump activity measured by accumulation and permeability studies. The accumulation
of efflux pump ligands (a) rhodamine 123 and (b) calcein AM was determined in cotreatment with sucrose esters, reference absorption enhancers,
verapamil, and cyclosporin A on confluent Caco-2 cells. The effects of sucrose esters and reference absorption enhancers on the apparent
permeability coefficients of (c) rhodamine 123 and (d) vinblastine in two directions were measured on confluent Caco-2 cell layers. Data are
presented as mean ± SD, n = 3–6; statistical analysis: ANOVA followed by Dunnett test (a and b) or two-way ANOVA followed by Bonferroni test
(c and d); *p< 0.05, **p< 0.01, ***p< 0.001; all groups were compared with control. Applied concentrations: P-1695, 30 :g/mL; M-1695, 60 :g/mL;
D-1216, 100 :g/mL; Tween 80, 1000 :g/mL; Cremophor RH40, 1000 :g/mL; verapamil, 100 :M; and cyclosporine A, 10 :M. Abbreviations: Papp,
apparent permeability coefficient; R123, rhodamine 123; C, control; P, P-1695; M, M-1695; D, D-1216; Tw, Tween 80; CR, Cremophor RH40; Ver,
verapamil; and Cyc A, cyclosporine A.
line (Fig. 6). Cells with enhanced membrane permeability were
gated out by TO-PRO3 staining; therefore, in this assay, only P-
gp inhibition was detected. The calcein accumulation observed
in the absence of P-gp in MES-SA cells was not influenced by
treatments. Because of the high-level expression of P-gp, MES-
SA/Dx5 cells showed reduced calcein accumulation. The P-gp-
inhibitor verapamil (100 :M) increased the fluorescent dye up-
take to the level of the control cell line. Except for Tween 80,
the surfactants did not influence the accumulation of calcein,
indicating a lack of interaction with P-gp.
DISCUSSION
The present study describes the effect of three sucrose esters
with same hydrophilic–lipophilic balance (HLB) value of 16 but
different fatty acid chain length (C12-C16) (Supplementary Ta-
ble S1) on cellular toxicity, drug permeability, intercellular junc-
tion morphology, efflux pump activity, and plasma membrane
fluidity, giving amore complex and detailed view on their action
on cultured intestinal epithelial cells than previous works.
Sucrose Esters and Viability of Cultured Epithelial Cells
On Caco-2 cells, D-1216 laurate ester (C12) was the least toxic,
whereas M-1695 myristate (C14) and P-1695 palmitate (C16)
ester had higher toxicity at both 1- or 24-h treatments (Fig. 1;
Table 1). The same results were obtained by these sucrose es-
ters in our previous works on Caco-2 intestinal44 and on RPMI
2650 humannasal epithelial cell lines.34 The same range of non-
toxic concentrations were described for an unspecified sucrose
monoester in Caco-2 cells,45 and for sucrose laurate, Tween
80, and Cremophor RH40 on MDCK dog kidney cells and two
MDCK-derived cell lines.24 In our previous study on Cremophor
RH40 and EL, similar toxicity results were obtained on intesti-
nal epithelial and brain endothelial cells.6 Increased MTT dye
conversion by Cremophor RH40 (Fig. 1a) was also observed
previously.6 MTT assay involves several cellular processes,46
which may be influenced by Cremophors. The toxic concen-
tration of the reference surfactants was at least one order of
magnitude higher in our studies and in the literature indicat-
ing that Tween 80 and Cremophor RH40 have a safer toxicity
profile on cultured cells than sucrose esters.
In contrast to cell culture works, sucrose esters did not dam-
age palatal and buccal pork tissues.20 Animal studies indicate
that sucrose fatty acid esters are hydrolyzed by intestinal en-
zymes into sucrose and fatty acids and that their metabolites
are not toxic.47–49 In addition, sucrose esters are chemically hy-
drolyzed under acidic or basic conditions50,51 and can be dis-
integrated by bacterial lipases.52 Tween 80 and Cremophor
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Figure 6. Effect of surfactants on calcein AM accumulation in P-gp positive MES-SA/Dx5 and P-gp negative MES-SA cell lines. Cellular calcein
AM fluorescence was determined after the treatments with vehicle (dark gray), verapamil (light gray), and surfactants (black) and is shown in
histogram. Applied concentrations: P-1695, 30 :g/mL; M-1695, 30 :g/mL; D-1216, 100 :g/mL; Tween 80, 100 :g/mL; Cremophor RH40, 1000
:g/mL; verapamil, 100 :M. Abbreviations: C, control; P, P-1695; M, M-1695; D, D-1216; Tw, Tween 80; CR, Cremophor RH40; Ver, verapamil.
The assay was repeated three times; the histograms show data from a representative experiment.
RH40 are also degraded in the intestine or in the blood,53,54
but the effects of the metabolites are unknown. A recent re-
view drew the attention to the dangers of using surfactants
as food additives: the permeability enhancing and efflux pump
inhibitor properties of these emulsifiers may cause intestinal
barrier dysfunction and increase the incidence of allergic and
autoimmune diseases,55 but conclusive animal studies and hu-
man data are missing. Despite the results of cell culture tests
and the hypothesized dangers of surfactants ingested as ad-
ditives in large quantities from foodstuff, the animal studies
suggest that the toxicity of sucrose esters might be lower,
if any, when given orally in small quantities as excipients.
However, further chronic toxicity experiments are needed to
prove the safety of sucrose esters as potential oral excipients.
Sucrose Esters and the Permeability of Intestinal Epithelial Cells
The tested surfactants possess high HLB as recommended for
absorption enhancers in pharmaceutical applications.11,20 Sev-
eral methods were used to determine the effect of sucrose esters
on the paracellular and transcellular permeability.
Sucrose esters decreased the resistance and impedance of ep-
ithelial cell layers reflecting elevated ion penetration through
the paracellular and transcellular pathways (Figs. 2a and 2b).
Resistance of Caco-2 cell layers also dropped after treatment
with sucrose esters in another study.45 Reference surfactants
did not change TEER of Caco-2 monolayers in the present
experiments, our previous works,6 and in two independent
studies,56,57 indicating no effect on ion permeability through
TJs. The resistance and impedancemeasurements suggest that
sucrose esters enhance ion permeability through paracellular
and transcellular pathways (Fig. 7).
We described for the first time that sucrose esters elevated
the flux of the hydrophilic drug atenolol through Caco-2 cell lay-
ers, indicating the absorption-enhancer properties of these sur-
factants (Table 2). The tested excipients significantly increased
the penetration of fluorescein in a concentration-dependent
Figure 7. Sucrose esters and reference absorption enhancers may
increase the penetration of molecules in several ways. (a) Surfactants
enhance the dissolution of molecules and change plasmamembrane flu-
idity that contributes to enhanced delivery of agents. (b) Tween 80, but
not sucrose esters, inhibits P-gp. (c) Sucrose esters may alter the func-
tion but not the visible morphology of cellular junctions, whereas ref-
erence molecules have no effect. Abbreviations: CR, Cremophor RH40;
P-gp, P-glycoprotein; SE, sucrose esters; and Tw, Tween 80.
manner in the AB direction (Fig. 2c and Supplementary Figs.
S1a, S1b, and S2). Because treatments were applied apically,
similarly to per os drug administration, no permeability en-
hancement was observed in the opposite direction, except for
M-1695 myristate ester. The increased permeability in BA di-
rection induced by M-1695 may be linked to the highest drop
of resistance caused by this sucrose ester as compared with
others (Fig. 2b). The absorption-enhancing effects of sucrose
esters,11 especially laurate (D-1216), was demonstrated in sev-
eral in vivo investigations.19–22 Tween 80 and Cremophor RH40
increased fluorescein permeability only in higher concentra-
tions; therefore, sucrose esters are more effective in small con-
centrations (Supplementary Figs. S2a–S2c). Reference surfac-
tants enhanced the permeability of all compounds, except the
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lipophilic model drugs caffeine and antipyrine. These class I
compounds of the Biopharmaceutics Classification System are
highly soluble and have high permeability,58 and the tested
surfactants could not elevate further the already high perme-
ability. Both Tween 80 and Cremophor RH40 are excipients
in medicines (Tw: Fluxarix, Boostrix, Tubersol, Tripedia; CR:
Neoral), and their penetration-increasing effects in the present
study are in agreement with literature data.3,34,57,59,60
Immunostaining of junctional proteins, fluorescent labeling
of F-actin, and transmission electron microscopy were used
to visualize intercellular connections and demonstrate the in-
tegrity of the paracellular barrier (Fig. 3). It was observed for
the first time that sucrose esters, Tween 80 and Cremophor
RH40, did not cause any major change in the distribution of
immunostaining for junctional proteins claudin-1, ZO-1, and
$-catenin on Caco-2 cells at the applied concentrations. Our
previous work showed a similar effect for Cremophor RH40
on Caco-2 cells.6 Surfactants slightly changed the organization
of F-actin at the junctional region and basal part of the cells,
but did not cause visible opening of the junctions. This F-actin
redistribution can be linked to changes in the functional perme-
ability of the junctions.4 Cytoskeletal F-actin changes caused by
an undefined sucrose ester were also observed in Caco-2 cells.45
Surfactants did not change the morphology of TJs investigated
by electron microscopy. No disruption of junctions or cell layers
were observed by these morphological examinations, confirm-
ing the safety of the selected surfactant concentrations and that
sucrose esters do not cause visible damage of intercellular junc-
tions. Caco-2 cells allowed detailed imaging of interepithelial
junctions. Intestinal tissue is a more complex system to study
TJs but revealing pericellular junctional ring in high magni-
fication is technically difficult. The use of intestinal epithelial
cell line only is a limitation of the present study.
Sucrose esters fluidized the plasma membrane of living
Caco-2 cells at lower concentrations than reference absorp-
tion enhancers, and caused stronger TMA-DPH fluorescence
anisotropy reduction than Tween 80 or Cremophor RH40
(Fig. 4). Sucrose esters containing longer fatty acid chain in-
creased better the membrane fluidity at lower concentrations,
indicating a correlation between the length of fatty acid chain
and effect on membrane fluidity. The maximal fluidization con-
centrations did not coincide with the maximal permeability en-
hancer effect of the surfactants. Several factors influence the
membrane permeability of cells, including the fluidity of lipid
bilayers, plasma membrane thickness and elasticity, and pore
formation in the lipid layer.61,62 This study focused on mem-
brane fluidization, but other changes in cell membrane prop-
erties could contribute to the observed penetration-enhancer
effects. Other studies confirmed that surfactants, including our
reference excipients, increase the fluidity of cellular plasma
membranes, which is linked to enhanced membrane perme-
ability and changes in the activity of membrane transporters
and efflux pumps.63–65
The resistance, impedance, permeability, morphology, and
membrane fluidity measurements indicate that several mech-
anisms are involved in the absorption enhancer effect of su-
crose esters (Fig. 7). All the tested surfactants elevated plasma
membrane fluidity, which can contribute to increased transcel-
lular passage of molecules. Sucrose esters decreased both re-
sistance and impedance indicating an effect on the function
of intercellular junctions and cellular membranes, thus en-
hancing drug permeability through both the transcellular and
paracellular routes. Tween 80 and Cremophor RH40 changed
neither the morphology of intercellular junctions, nor the re-
sistance of cell layers, suggesting no effect on paracellular
transport.
Effects of Sucrose Esters on Efflux Pumps
Efflux transporters hinder drug delivery across biological barri-
ers and blocking these pumps is considered as a way to increase
drug penetration.66 Surfactants were described to inhibit up-
take transporters,67 as well as efflux pumps.68,69 The effect of
sucrose esters on efflux pumps is contradictory with studies
describing inhibitory23,24 or no effect.18 In the present exper-
iments, sucrose esters, unlike inhibitors or reference surfac-
tants, increased the permeability of vinblastine and rhodamine
123 in AB, but not in the other direction, suggesting no in-
hibitory effect on efflux pumps (Figs. 5c and 5d). Sucrose es-
ters elevated rhodamine 123 and calcein AM accumulation in
cotreatment, which may have suggested an inhibitory effect of
efflux transporters. However, our experiments conducted on a
model cell line expressing P-gp ruled out this possibility, as
the sucrose esters did not influence the P-gp-mediated efflux
in MES-SA/Dx5 cells (Fig. 6). Takaishi et al.18 suggested that
elevated daunomycine flux in Caco-2 cells caused by sucrose
esters is because of the permeabilization of the cellular mem-
brane, but the present study is the first to experimentally prove
that enhanced permeability is unrelated to P-gp.
Reference surfactants significantly increased the accumula-
tion of rhodamine 123 in both pretreatment and cotreatment
conditions. The uptake of calcein AM in Caco-2 cells was in-
creased by Tween 80 and efflux pump inhibitors, but not by
Cremophor RH40. The difference in the rhodamine and calcein
AM uptake assays may be explained by the different speci-
ficity of the dyes: rhodamine 123 is a ligand of P-gp and BCRP,
whereas calcein AM is a ligand of P-gp and MRP-1 and MRP-
2.24,43 Reference surfactants significantly increased the pen-
etration of rhodamine 123 and vinblastine in AB direction,
but reduced the permeability in the other direction only for
rhodamine. Vinblastine is a ligand of both P-gp and MRP-2
that may explain the difference. Calcein AM uptake in P-gp-
expressing MES-SA/Dx5 cells verified that Tween 80 is a P-gp
inhibitor (Fig. 6). Our data indicate an inhibitory effect of the
reference surfactants on efflux pump activity (Fig. 7) in agree-
ment with other studies on Tween 803,23,24,65,67 and Cremophor
RH40.24,70
CONCLUSIONS
Sucrose esters are increasingly used as inactive ingredients
in pharmaceutical products. Our study on cultured epithelial
cells confirmed that sucrose esters are effective absorption en-
hancers for both hydrophilic drugs and efflux pump ligands.
Sucrose esters enhance drug penetration by the transcellular
and paracellular routes, but do not inhibit P-gp. It was demon-
strated for the first time that sucrose esters fluidize the plasma
membrane of epithelial cells in low concentrations. Reference
surfactants Tween 80 and Cremophor RH 40 increase drug
penetration by the transcellular pathway and inhibition of ef-
flux pump activity and not by acting on intercellular junctions.
Sucrose esters as oral excipients may act differently than the
reference absorption enhancers; therefore, further studies are
needed to optimize oral dosage forms with these surfactants.
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Curve fitting for toxicity data 
For the toxicity assays the non-toxic concentrations (TC0), 50 % toxic concentrations (TC50) and 
concentrations causing death in all cell (TC100) were calculated from fitted curves (GraphPad Prism 5.0, 
GraphPad Software Inc., San Diego, CA, USA) using the following equation: 
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At the first step the logTC50 was calculated by Eq. (1), then TC0 and TC100 were further analyzed by Eq. (2). 
The ECF is the concentration of surfactants that gives a response F percent (0 % or 100 %) of the way between 
Bottom and Top. HillSlope describes the steepness of the family of curves. Top and Bottom are plateaus in the 
units of the Y axis. 
 
Calculation of clearance and apparent permeability coefficients 
For the permeability measurments the apparent permeability coefficient (Papp) in apical to basal (AB) direction 
was calculated by this equation: 
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where [C]B is the concentration of the tracer in the basal compartment after 1 hour; [C]A is the concentration in 
the apical compartment at 0 hour; VB is the volume of the basal compartment (1.5 ml); A is the surface area 
available for transport (1.12 cm2); t is the length of the time of the transport assay (1 hour). To calculate the 
apparent permeability of the opposite transport direction (BA) the following equation was used: 
 
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where [C]A was the concentration of the tracer in apical compartment after 1 hour; [C]B is the concentration in 
basal compartment at 0 hour, and VA is the volume of the apical compartment (0.5 ml). Clearance of vinblastine 
and fluorescein was also determined at different time points in both penetration directions, using the following 
equations: 
 
 Donor
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C
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
600
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  Eq.(5)
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where Clt60 and Clt120 was the clearance at 60 and 120 minutes, [Ct0-60]Accep and [Ct60-120]Accep was the 
concentration of the tracer in acceptor compartment after 60 and 120 minutes, Vaccep was the volume of acceptor 
phase, [C]Donor was the concentration at the beginning of the experiment. The average cleared volumes were 
plotted vs. time, and lines were fitted using the least squares method. The slope (µl/min) of the fitted line was 
used to calculate the apparent permeability by the following equation: 
tA
Slope

(cm/s) Papp
  Eq.(7)
 
where A is the surface area available for transport (112 mm2); t is 60 seconds. 
 
 
 Supporting table 
 
 P-1695 M-1695 D-1216 
Chemical 
structure 
 
R- carbon 
chain lenght 
16 14 12 
HLB 16 16 16 
CMC 28-250 µM 71 28-250 µM 71 500 µg/ml 72 
Trade name Ryoto sugar ester P-
1695 
Ryoto sugar ester M-
1695 
Surfhope SE Pharma D-
1216 (US DMF) 
Chemical 
name 
palmitate sucrose ester 
myristate sucrose ester 
laurate sucrose ester 
Solubility water soluble water soluble water soluble 
 
 
Polysorbate 80 (Ph.Eur.) Macrogol-glycerolhydroxystearate 
40 (Ph.Eur.) 
Chemical 
structure 
 
  
R- carbon 
chain lenght 
18 18 
HLB 15 15 
CMC 50-63µg/ml 53,59 390 µg/ml 50 
Trade name Tween 80 Cremophor RH40 
Chemical 
name 
polyethoxylatedsorbitan and oleic 
acid 
polyethoxylated 40 hydrogenated 
castor oil 
Solubility water soluble water soluble 
 
Table S1. Properties of surfactants 
R- carbon chain length, carbon chain length of fatty acid residues; CMC: critical micelle concentration; HLB: 
hydrophilic-lipophilic balance; US DMF, US drug master file.; Ph.Eur., European Pharmacopoea. 
 
 Supporting figures 
 
 
Figure S1. Effect of sucrose esters and reference surfactants on fluorescein and vinblastine 
clearance 
The effect of sucrose esters and reference absorption enhancers on clearance of fluorescein and vinblastine on 
confluent Caco-2 cell layers was measured at 60 and 120 minutes. The applied concentrations of surfactants: P-
1695, 30 µg/ml; M-1695, 60 µg/ml; D-1216, 100 µg/ml; Tween 80, 1000 µg/ml; Cremophor RH40, 1000 µg/ml. 
Abbreviations: C, control; P, P-1695; M, M-1695; D, D-1216; Tw, Tween 80; CR, Cremophor RH40. 
 
 
  
 
Figure S2. Effect of sucrose esters and reference surfactants on fluorescein permeability  
The effect of sucrose esters and reference absorption enhancers on the apparent permeability coefficients of 
fluorescein on confluent Caco-2 cell layers applied in the same concentrations of (a) 30 µg/ml, (b) 60 µg/ml, 
(c) 100 µg/ml. Data are presented as mean ± S.D., n = 3; statistical analysis: ANOVA followed by Dunnett test; 
***P < 0.001, all groups were compared to control. Abbreviations: Papp, apparent permeability coefficient; C, 
control; P, P-1695; M, M-1695; D, D-1216; Tw, Tween 80; CR, Cremophor RH40. 
 
  
 
Figure S3. Effects of surfactants, cytochalasin D and Triton X-100 on actin cytoskeleton 
Fluorescent staining for F-actin cytoskeletal protein with phalloidin labeled by Alexa Fluor 488 in human Caco-
2 intestinal epithelial cells after 1 hour treatment with sucrose esters, reference absorption enhancers, 
cytochalasin D or Triton X-100. Images were captured from two regions of cells after treatment with absorption 
enhancers: apical and basal part; and three different region of cells with treatment by cytochalasin D and Triton 
X-100: apical, junctional and basal part. Abbreviations: C, control; M, M-1695; P, P-1695; D, D-1216; Tw, 
Tween 80; CR, Cremophor RH40; CCD, cytochalasin D; TX, Triton X-100. Bar = 15 µm. 
 
  
 
 
Figure S4. Effect of pre-treatment with surfactants on efflux pump activity 
Effect of pre-treatment with sucrose esters, reference absorption enhancers, verapamil and cyclosporin A on the 
accumulation of efflux pump ligand (a) rhodamine 123 and (b) calcein AM in confluent Caco-2 cell layers. Data 
are presented as mean ± S.D., n = 6; statistical analysis: ANOVA followed by Dunnett test; *P < 0.05, 
**P < 0.01, ***P < 0.001, all groups were compared to control. Applied concentrations: M-1695, 60 µg/ml; P-
1695, 30 µg/ml; D-1216, 100 µg/ml; Tween 80, 1000 µg/ml; Cremophor RH40, 1000 µg/ml; verapamil, 
100 µM; cyclosporine A, 10 µM. Abbreviations: R123, Rhodamine 123; C, control; M, M-1695; P, P-1695; D, 
D-1216; Tw, Tween 80; CR, Cremophor RH40; Ver, verapamil; Cyc A, cyclosporine A. 
